activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2147225	CHEMBL929104	Activity of human CK2-alpha-2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	120.0	CHEMBL4070	Homo sapiens	Activity	%	120.0
	2147225	CHEMBL929104	Activity of human CK2-alpha-2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	120.0	CHEMBL4070	Homo sapiens	Activity	%	120.0
	2279752	CHEMBL958317	Inhibition of CK2alpha2	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1		CHEMBL493937	=	IC50	nM	701.0	CHEMBL4070	Homo sapiens	IC50	nM	701.0
	2279754	CHEMBL958319	Inhibition of CK2alpha2 at 10 uM	B	COC(=O)/C=C/c1cccc(-c2cncc(N3CCCN(C)CC3)n2)c1		CHEMBL521831	=	Inhibition	%	7.0	CHEMBL4070	Homo sapiens	INH	%	7.0
	2279756	CHEMBL958319	Inhibition of CK2alpha2 at 10 uM	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(N)=O)c3)n2)CC1		CHEMBL493536	=	Inhibition	%	36.0	CHEMBL4070	Homo sapiens	INH	%	36.0
	2470143	CHEMBL1034092	Inhibition of CSNK2A2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL4070	Homo sapiens	INH	%	10.0
Not Evaluated	2476763	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2478602	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL4070	Homo sapiens	Activity		
	2478805	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	9.4	CHEMBL4070	Homo sapiens	Activity	%	9.4
Not Evaluated	2479660	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL4070	Homo sapiens	Activity		
	2479863	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Activity	%	17.3	CHEMBL4070	Homo sapiens	Activity	%	17.3
Active	2480660	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL4070	Homo sapiens	Activity		
	2480862	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	6.8	CHEMBL4070	Homo sapiens	Activity	%	6.8
Not Evaluated	2577281	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2577484	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2593689	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2593955	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2594158	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2594898	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2595101	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL4070	Homo sapiens	Activity		
	2595817	CHEMBL1017884	Inhibition of CSNK2A2 assessed as enzyme activity relative to control	B	C[C@@H]1CCN(C(=O)CC#N)C[C@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL459977	=	Activity	%	34.0	CHEMBL4070	Homo sapiens	Activity	%	34.0
	2596298	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342	=	Activity	%	17.7	CHEMBL4070	Homo sapiens	Activity	%	17.7
Not Evaluated	2596501	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL4070	Homo sapiens	Activity		
Not Evaluated	2597770	CHEMBL983561	Binding affinity to human CK2A2 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL4070	Homo sapiens	Activity		
	2893277	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893278	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893279	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893280	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893281	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893282	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893283	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1600.0	CHEMBL4070	Homo sapiens	Kd	nM	1600.0
	2893284	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893285	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893286	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893287	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893288	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893289	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893290	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893291	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893292	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893293	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893294	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893295	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893296	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	2000.0	CHEMBL4070	Homo sapiens	Kd	nM	2000.0
	2893297	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893298	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	3400.0	CHEMBL4070	Homo sapiens	Kd	nM	3400.0
	2893299	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893300	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893301	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893302	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893303	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893304	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893305	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893306	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893307	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893308	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893309	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	6.5	CHEMBL4070	Homo sapiens	Kd	nM	6.5
	2893310	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	140.0	CHEMBL4070	Homo sapiens	Kd	nM	140.0
	2893311	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	370.0	CHEMBL4070	Homo sapiens	Kd	nM	370.0
	2893312	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	400.0	CHEMBL4070	Homo sapiens	Kd	nM	400.0
	2893313	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2893314	CHEMBL1061141	Binding constant for full-length CSNK2A2	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	2921385	CHEMBL1055283	Inhibition of CSNK2A2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	3052571	CHEMBL1037112	Residual activity of CK2alpha2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	89.0	CHEMBL4070	Homo sapiens	Residual activity	%	89.0
	3053880	CHEMBL1044280	Residual activity of CK2alpha2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	116.0	CHEMBL4070	Homo sapiens	Residual activity	%	116.0
	3054132	CHEMBL1040236	Residual activity of CK2alpha2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	98.0	CHEMBL4070	Homo sapiens	Residual activity	%	98.0
	3055419	CHEMBL1037112	Residual activity of CK2alpha2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	96.0	CHEMBL4070	Homo sapiens	Residual activity	%	96.0
	3055671	CHEMBL1044280	Residual activity of CK2alpha2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	98.0	CHEMBL4070	Homo sapiens	Residual activity	%	98.0
	3056976	CHEMBL1040236	Residual activity of CK2alpha2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	91.0	CHEMBL4070	Homo sapiens	Residual activity	%	91.0
	3058296	CHEMBL1037112	Residual activity of CK2alpha2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	88.0	CHEMBL4070	Homo sapiens	Residual activity	%	88.0
	3058548	CHEMBL1044280	Residual activity of CK2alpha2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	97.0	CHEMBL4070	Homo sapiens	Residual activity	%	97.0
	3072894	CHEMBL1040236	Residual activity of CK2alpha2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	88.0	CHEMBL4070	Homo sapiens	Residual activity	%	88.0
	3224793	CHEMBL1102787	Inhibition of CK2alpha2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3225043	CHEMBL1102787	Inhibition of CK2alpha2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3331886	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3333301	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3334706	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3336126	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3337493	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3337741	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3339073	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3340375	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3340654	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3342070	CHEMBL1168845	Inhibition of CSNK2A2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	3358519	CHEMBL1174307	Inhibition of CSNK2A2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	94.0	CHEMBL4070	Homo sapiens	INH	%	94.0
	3358961	CHEMBL1174307	Inhibition of CSNK2A2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	78.0	CHEMBL4070	Homo sapiens	INH	%	78.0
	3443372	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	11.0	CHEMBL4070	Homo sapiens	INH	%	11.0
	3443589	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	7.0	CHEMBL4070	Homo sapiens	INH	%	7.0
	3444744	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	9.0	CHEMBL4070	Homo sapiens	INH	%	9.0
	3445074	CHEMBL1244783	Binding affinity to CSNK2A2	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	180.0	CHEMBL4070	Homo sapiens	Kd	nM	180.0
	3445368	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	6.0	CHEMBL4070	Homo sapiens	INH	%	6.0
	3445585	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	14.0	CHEMBL4070	Homo sapiens	INH	%	14.0
	3445797	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	9.0	CHEMBL4070	Homo sapiens	INH	%	9.0
	3445987	CHEMBL1244405	Inhibition of CK2alpha2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	0.0	CHEMBL4070	Homo sapiens	INH	%	0.0
	3448391	CHEMBL1244783	Binding affinity to CSNK2A2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	3448725	CHEMBL1244783	Binding affinity to CSNK2A2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	3449145	CHEMBL1244783	Binding affinity to CSNK2A2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	370.0	CHEMBL4070	Homo sapiens	Kd	nM	370.0
	3449618	CHEMBL1244783	Binding affinity to CSNK2A2	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	3450040	CHEMBL1244783	Binding affinity to CSNK2A2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	3450959	CHEMBL1244783	Binding affinity to CSNK2A2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	uM	10.0
	3463205	CHEMBL1252293	Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	6.0	CHEMBL4070	Homo sapiens	INH	%	6.0
	3463424	CHEMBL1252293	Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	27.0	CHEMBL4070	Homo sapiens	INH	%	27.0
	3463968	CHEMBL1252293	Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	26.0	CHEMBL4070	Homo sapiens	INH	%	26.0
	5120399	CHEMBL1648372	Inhibition of human CK2a2 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	108.0	CHEMBL4070	Homo sapiens	INH	%	108.0
	6227702	CHEMBL1786245	Inhibition of CSNK2A2 at 100 nM relative to control	B	O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1		CHEMBL1782521	=	Inhibition	%	28.0	CHEMBL4070	Homo sapiens	INH	%	28.0
	6341038	CHEMBL1828207	Activity of CSNK2A2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	7567244	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7567703	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7568174	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7568632	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	300.0	CHEMBL4070	Homo sapiens	Kd	nM	300.0
	7569217	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7569677	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7570149	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	3300.0	CHEMBL4070	Homo sapiens	Kd	nM	3300.0
	7570170	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	5600.0	CHEMBL4070	Homo sapiens	Kd	nM	5600.0
	7570597	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	160.0	CHEMBL4070	Homo sapiens	Kd	nM	160.0
	7571193	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7571650	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7572147	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Kd	nM	2900.0	CHEMBL4070	Homo sapiens	Kd	nM	2900.0
	7572563	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	9600.0	CHEMBL4070	Homo sapiens	Kd	nM	9600.0
	7573174	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	890.0	CHEMBL4070	Homo sapiens	Kd	nM	890.0
	7573665	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	6200.0	CHEMBL4070	Homo sapiens	Kd	nM	6200.0
	7574134	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7574542	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	=	Kd	nM	1500.0	CHEMBL4070	Homo sapiens	Kd	nM	1500.0
	7575171	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7575642	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7576107	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7576515	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	120.0	CHEMBL4070	Homo sapiens	Kd	nM	120.0
	7576684	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7577143	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	2800.0	CHEMBL4070	Homo sapiens	Kd	nM	2800.0
	7577621	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	230.0	CHEMBL4070	Homo sapiens	Kd	nM	230.0
	7578091	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	940.0	CHEMBL4070	Homo sapiens	Kd	nM	940.0
	7578496	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7578692	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	3800.0	CHEMBL4070	Homo sapiens	Kd	nM	3800.0
	7579066	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7579516	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7579990	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7580459	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7580862	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7581050	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7581435	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7581880	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7582351	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7582815	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	14.0	CHEMBL4070	Homo sapiens	Kd	nM	14.0
	7583396	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7583793	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7584238	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	Kd	nM	2400.0	CHEMBL4070	Homo sapiens	Kd	nM	2400.0
	7584709	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	6700.0	CHEMBL4070	Homo sapiens	Kd	nM	6700.0
	7585133	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7585726	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7586134	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7586580	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7587063	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7587687	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	=	Kd	nM	2800.0	CHEMBL4070	Homo sapiens	Kd	nM	2800.0
	7588106	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	970.0	CHEMBL4070	Homo sapiens	Kd	nM	970.0
	7588588	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7589039	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7589652	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7590076	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	200.0	CHEMBL4070	Homo sapiens	Kd	nM	200.0
	7590101	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7590575	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7591026	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7591625	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7592077	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	=	Kd	nM	990.0	CHEMBL4070	Homo sapiens	Kd	nM	990.0
	7592550	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7593003	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7593585	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7594057	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7594530	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7594982	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7595118	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7595562	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7596036	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7596507	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7596954	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	230.0	CHEMBL4070	Homo sapiens	Kd	nM	230.0
	7597090	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7597543	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7598016	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7598486	CHEMBL1908546	Binding constant for CSNK2A2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL4070	Homo sapiens	Kd	nM	10000.0
	7922692	CHEMBL1918454	Inhibition of human recombinant CK2alpha2 at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	27.0	CHEMBL4070	Homo sapiens	INH	%	27.0
	7929264	CHEMBL1918724	Inhibition of CK2alpha at 1 uM	B	CC(=O)Nc1cn2cc(/C=C3\SC(=O)NC3=O)ccc2n1		CHEMBL1914475	=	Inhibition	%	95.0	CHEMBL4070	Homo sapiens	INH	%	95.0
	7978971	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	270.0	CHEMBL4070	Homo sapiens	Ki	nM	270.0
	7978972	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Ic1c(I)c(I)c2[nH]cnc2c1I		CHEMBL595730	=	Ki	nM	71.0	CHEMBL4070	Homo sapiens	Ki	nM	71.0
	7978973	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	112.0	CHEMBL4070	Homo sapiens	Ki	nM	112.0
	7978974	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1C		CHEMBL375230	=	Ki	nM	109.0	CHEMBL4070	Homo sapiens	Ki	nM	109.0
	7978975	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL223082	=	Ki	nM	37.0	CHEMBL4070	Homo sapiens	Ki	nM	37.0
	7978976	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928903	=	Ki	nM	35.0	CHEMBL4070	Homo sapiens	Ki	nM	35.0
	7978977	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928904	=	Ki	nM	88.0	CHEMBL4070	Homo sapiens	Ki	nM	88.0
	7978978	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928905	=	Ki	nM	200.0	CHEMBL4070	Homo sapiens	Ki	nM	200.0
	7978979	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928906	=	Ki	nM	100.0	CHEMBL4070	Homo sapiens	Ki	nM	100.0
	7978980	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928907	=	Ki	nM	83.0	CHEMBL4070	Homo sapiens	Ki	nM	83.0
	7978981	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(I)c(I)c(I)c(I)c2[nH]1		CHEMBL610448	=	Ki	nM	78.0	CHEMBL4070	Homo sapiens	Ki	nM	78.0
	7978982	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL594575	=	Ki	nM	609.0	CHEMBL4070	Homo sapiens	Ki	nM	609.0
	7978983	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928908	=	Ki	nM	188.0	CHEMBL4070	Homo sapiens	Ki	nM	188.0
	7978984	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CC(=O)O		CHEMBL1233807	=	Ki	nM	66.0	CHEMBL4070	Homo sapiens	Ki	nM	66.0
	7978985	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCC(=O)O		CHEMBL1928909	=	Ki	nM	139.0	CHEMBL4070	Homo sapiens	Ki	nM	139.0
	7978986	CHEMBL1930611	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(I)c(I)c(I)c(I)c21		CHEMBL593153	=	Ki	nM	62.0	CHEMBL4070	Homo sapiens	Ki	nM	62.0
	7978987	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	343.0	CHEMBL4070	Homo sapiens	Ki	nM	343.0
	7978988	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Ic1c(I)c(I)c2[nH]cnc2c1I		CHEMBL595730	=	Ki	nM	21.0	CHEMBL4070	Homo sapiens	Ki	nM	21.0
	7978989	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	133.0	CHEMBL4070	Homo sapiens	Ki	nM	133.0
	7978990	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1C		CHEMBL375230	=	Ki	nM	35.0	CHEMBL4070	Homo sapiens	Ki	nM	35.0
	7978991	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL223082	=	Ki	nM	49.0	CHEMBL4070	Homo sapiens	Ki	nM	49.0
	7978992	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928903	=	Ki	nM	31.0	CHEMBL4070	Homo sapiens	Ki	nM	31.0
	7978993	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928904	=	Ki	nM	44.0	CHEMBL4070	Homo sapiens	Ki	nM	44.0
	7978994	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928905	=	Ki	nM	24.0	CHEMBL4070	Homo sapiens	Ki	nM	24.0
	7978995	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928906	=	Ki	nM	55.0	CHEMBL4070	Homo sapiens	Ki	nM	55.0
	7978996	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928907	=	Ki	nM	768.0	CHEMBL4070	Homo sapiens	Ki	nM	768.0
	7978997	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(I)c(I)c(I)c(I)c2[nH]1		CHEMBL610448	=	Ki	nM	106.0	CHEMBL4070	Homo sapiens	Ki	nM	106.0
	7978998	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL594575	=	Ki	nM	342.0	CHEMBL4070	Homo sapiens	Ki	nM	342.0
	7978999	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928908	=	Ki	nM	195.0	CHEMBL4070	Homo sapiens	Ki	nM	195.0
	7979000	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CC(=O)O		CHEMBL1233807	=	Ki	nM	21.0	CHEMBL4070	Homo sapiens	Ki	nM	21.0
	7979001	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCC(=O)O		CHEMBL1928909	=	Ki	nM	93.0	CHEMBL4070	Homo sapiens	Ki	nM	93.0
	7979002	CHEMBL1930612	Inhibition of human CK2 alpha' catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(I)c(I)c(I)c(I)c21		CHEMBL593153	=	Ki	nM	324.0	CHEMBL4070	Homo sapiens	Ki	nM	324.0
	7982615	CHEMBL1937142	Inhibition of CSNK2A2 at 10 uM after 1 hr by competitive binding assay	B	CCOC(=O)C[C@@H]1[C@@H](CNC(=O)NC)O[C@@H](n2cnc3c(NC(=O)Nc4ccccc4)ncnc32)[C@@H]1O[Si](C)(C)C(C)(C)C		CHEMBL1076310	=	Inhibition	%	31.0	CHEMBL4070	Homo sapiens	INH	%	31.0
	8002152	CHEMBL1942256	Inhibition of CSNK2A2 at 1 uM	B	CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21		CHEMBL1940251	=	Inhibition	%	4.0	CHEMBL4070	Homo sapiens	INH	%	4.0
	8002153	CHEMBL1942256	Inhibition of CSNK2A2 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1		CHEMBL1940252	=	Inhibition	%	8.0	CHEMBL4070	Homo sapiens	INH	%	8.0
	8002154	CHEMBL1942256	Inhibition of CSNK2A2 at 1 uM	B	CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1		CHEMBL1940253	=	Inhibition	%	2.0	CHEMBL4070	Homo sapiens	INH	%	2.0
	8012904	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	CCN1CCC2(CC1)NC(=O)c1c(c3ccc(Cl)c(Cl)c3n1C)C2C#N		CHEMBL1945557	=	Delta Tm	degrees C	1.8	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.8
	8012929	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCN(C(=O)OC(C)(C)C)CC1)NC2=O		CHEMBL1945558	=	Delta Tm	degrees C	0.3	CHEMBL4070	Homo sapiens	deltaTm	degrees C	0.3
	8012953	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O		CHEMBL1945559	=	Delta Tm	degrees C	4.2	CHEMBL4070	Homo sapiens	deltaTm	degrees C	4.2
	8012977	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	N#CC1c2c([nH]c3c(Cl)c(Cl)ccc23)C(=O)NC12CCCCC2		CHEMBL1945560	=	Delta Tm	degrees C	1.2	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.2
	8013001	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(CN)C(C)(C)NC2=O		CHEMBL1945561	=	Delta Tm	degrees C	0.5	CHEMBL4070	Homo sapiens	deltaTm	degrees C	0.5
	8013026	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	CC(=O)NCC1c2c(n(C)c3c(Cl)c(Cl)ccc23)C(=O)NC1(C)C		CHEMBL1945562	=	Delta Tm	degrees C	1.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.0
	8026918	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(Cl)c(Cl)ccc2c2cc[nH]c(=O)c21		CHEMBL474872	=	Delta Tm	degrees C	2.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	2.0
	8027530	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(Cl)c(Cl)ccc2c2cc(N)[nH]c(=O)c21		CHEMBL1945336	=	Delta Tm	degrees C	3.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	3.0
	8027555	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C(C)(C)NC2=O		CHEMBL1945337	=	Delta Tm	degrees C	2.1	CHEMBL4070	Homo sapiens	deltaTm	degrees C	2.1
	8027580	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	CC1(C)NC(=O)c2[nH]c3c(Cl)c(Cl)ccc3c2C1C#N		CHEMBL1945338	=	Delta Tm	degrees C	1.9	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.9
	8027605	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	CCC1(CC)NC(=O)c2c(c3ccc(Cl)c(Cl)c3n2C)C1C#N		CHEMBL1945339	=	Delta Tm	degrees C	1.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.0
	8027630	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccccc31)C(C#N)C(C)(C)NC2=O		CHEMBL1945340	=	Delta Tm	degrees C	0.7	CHEMBL4070	Homo sapiens	deltaTm	degrees C	0.7
	8027654	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCCCC1)NC2=O		CHEMBL1945341	=	Delta Tm	degrees C	0.8	CHEMBL4070	Homo sapiens	deltaTm	degrees C	0.8
	8027666	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCCC1)NC2=O		CHEMBL1945554	=	Delta Tm	degrees C	1.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.0
	8027691	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCOCC1)NC2=O		CHEMBL1945335	=	Delta Tm	degrees C	1.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	1.0
	8027716	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	Cn1c2c(Cl)c(Cl)ccc2c2cn[nH]c(=O)c21		CHEMBL1945555	=	Delta Tm	degrees C	2.1	CHEMBL4070	Homo sapiens	deltaTm	degrees C	2.1
	8027741	CHEMBL1949031	Binding affinity to CK2alpha2 assessed as change in thermal denaturation at 10 uM by thermal stability shift assay	B	CN1CCC2(CC1)NC(=O)c1c(c3ccc(Cl)c(Cl)c3n1C)C2C#N		CHEMBL1945556	=	Delta Tm	degrees C	2.7	CHEMBL4070	Homo sapiens	deltaTm	degrees C	2.7
	10925160	CHEMBL2046111	Inhibition of human CK2alpha2 assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	CC(C)Nc1cc(-c2oc3ccccc3c(=O)c2-c2ccc(F)cc2)ccn1		CHEMBL2041958	=	Activity	%	105.0	CHEMBL4070	Homo sapiens	Activity	%	105.0
	10925161	CHEMBL2046111	Inhibition of human CK2alpha2 assessed as remaining activity at 0.8 uM after 40 mins by scintillation counting	B	O=c1c(-c2ccc(F)cc2)c(-c2ccnc(NC3CCCCC3)c2)oc2ccccc12		CHEMBL2041962	=	Activity	%	104.0	CHEMBL4070	Homo sapiens	Activity	%	104.0
	11013390	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(=O)Nc1nnc(-c2ccc([N+](=O)[O-])cc2)s1		CHEMBL2087004	=	IC50	nM	32200.0	CHEMBL4070	Homo sapiens	IC50	uM	32.2
	11013392	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087005	=	IC50	nM	5300.0	CHEMBL4070	Homo sapiens	IC50	uM	5.3
	11013394	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccccc3)s2)cc1		CHEMBL2087006	=	IC50	nM	3300.0	CHEMBL4070	Homo sapiens	IC50	uM	3.3
	11013396	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccc(F)cc3)s2)cc1		CHEMBL2087007	=	IC50	nM	1700.0	CHEMBL4070	Homo sapiens	IC50	uM	1.7
	11013398	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2nnc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087008	=	IC50	nM	1200.0	CHEMBL4070	Homo sapiens	IC50	uM	1.2
	11013400	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3cccs3)s2)cc1		CHEMBL2087009	=	IC50	nM	5800.0	CHEMBL4070	Homo sapiens	IC50	uM	5.8
	11013402	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccco3)s2)cc1		CHEMBL2087010	=	IC50	nM	1800.0	CHEMBL4070	Homo sapiens	IC50	uM	1.8
	11013404	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(CO)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087011	=	IC50	nM	2800.0	CHEMBL4070	Homo sapiens	IC50	uM	2.8
	11013406	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COCC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087012	=	IC50	nM	4300.0	CHEMBL4070	Homo sapiens	IC50	uM	4.3
	11013408	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)C3CC3)s2)cc1		CHEMBL2087013	=	IC50	nM	1600.0	CHEMBL4070	Homo sapiens	IC50	uM	1.6
	11013410	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	C/C=C(\C)C(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087014	=	IC50	nM	2900.0	CHEMBL4070	Homo sapiens	IC50	uM	2.9
	11013412	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087015	=	IC50	nM	4300.0	CHEMBL4070	Homo sapiens	IC50	uM	4.3
	11013414	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	C=CCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087016	=	IC50	nM	2700.0	CHEMBL4070	Homo sapiens	IC50	uM	2.7
	11013416	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087017	=	IC50	nM	3000.0	CHEMBL4070	Homo sapiens	IC50	uM	3.0
	11013418	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(C)OC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087018	=	IC50	nM	8200.0	CHEMBL4070	Homo sapiens	IC50	uM	8.2
	11013420	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087019	=	IC50	nM	3100.0	CHEMBL4070	Homo sapiens	IC50	uM	3.1
	11013422	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(C)COC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087020	=	IC50	nM	5700.0	CHEMBL4070	Homo sapiens	IC50	uM	5.7
	11013424	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087021	=	IC50	nM	2400.0	CHEMBL4070	Homo sapiens	IC50	uM	2.4
	11013426	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087022	=	IC50	nM	2100.0	CHEMBL4070	Homo sapiens	IC50	uM	2.1
	11013432	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)Cc1ccn(-c2cncc(-n3ncc4ccc(NC5CCCC5)cc43)n2)c1		CHEMBL2048144	=	IC50	nM	190.0	CHEMBL4070	Homo sapiens	IC50	uM	0.19
	11013433	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	IC50	nM	46.0	CHEMBL4070	Homo sapiens	IC50	uM	0.046
	11013434	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2nnc(-c3ccc(C(=O)O)cc3)o2)cc1		CHEMBL2087024	=	IC50	nM	32000.0	CHEMBL4070	Homo sapiens	IC50	uM	32.0
	11013435	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2cc(-c3ccc(C(=O)O)cc3)[nH]n2)cc1		CHEMBL2087025	=	IC50	nM	63.0	CHEMBL4070	Homo sapiens	IC50	uM	0.063
	11013436	CHEMBL2092254	Competitive inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2cnc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087026	=	IC50	nM	25000.0	CHEMBL4070	Homo sapiens	IC50	uM	25.0
	11013452	CHEMBL2092255	Inhibition of GST fused human CK2alpha' expressed in Escherichia coli BL21 at 0.3 uM	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	>	Inhibition	%	100.0	CHEMBL4070	Homo sapiens	INH	%	100.0
	12046272	CHEMBL2156509	Inhibition of CK2alpha2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	4.3	CHEMBL4070	Homo sapiens	INH	%	4.3
	12173671	CHEMBL2209306	Inhibition of CSNK2A2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	70.0	CHEMBL4070	Homo sapiens	Activity	%	70.0
	12183898	CHEMBL2211488	Inhibition of CSNK2A2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	pIC50		5.0
	12183906	CHEMBL2211478	Inhibition of CK2a2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	pIC50		5.0
	12217151	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217152	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	118.0	CHEMBL4070	Homo sapiens	Residual Activity	%	118.0
	12217153	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12217154	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217155	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	118.0	CHEMBL4070	Homo sapiens	Residual Activity	%	118.0
	12217156	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	113.0	CHEMBL4070	Homo sapiens	Residual Activity	%	113.0
	12217157	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	124.0	CHEMBL4070	Homo sapiens	Residual Activity	%	124.0
	12217158	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	128.0	CHEMBL4070	Homo sapiens	Residual Activity	%	128.0
	12217159	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	130.0	CHEMBL4070	Homo sapiens	Residual Activity	%	130.0
	12217160	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	126.0	CHEMBL4070	Homo sapiens	Residual Activity	%	126.0
	12217161	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217162	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217163	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	125.0	CHEMBL4070	Homo sapiens	Residual Activity	%	125.0
	12217164	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	118.0	CHEMBL4070	Homo sapiens	Residual Activity	%	118.0
	12217165	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	122.0	CHEMBL4070	Homo sapiens	Residual Activity	%	122.0
	12217166	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	131.0	CHEMBL4070	Homo sapiens	Residual Activity	%	131.0
	12217167	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	134.0	CHEMBL4070	Homo sapiens	Residual Activity	%	134.0
	12217168	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	126.0	CHEMBL4070	Homo sapiens	Residual Activity	%	126.0
	12217169	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	126.0	CHEMBL4070	Homo sapiens	Residual Activity	%	126.0
	12217170	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217171	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	132.0	CHEMBL4070	Homo sapiens	Residual Activity	%	132.0
	12217172	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	125.0	CHEMBL4070	Homo sapiens	Residual Activity	%	125.0
	12217173	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	134.0	CHEMBL4070	Homo sapiens	Residual Activity	%	134.0
	12217174	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	123.0	CHEMBL4070	Homo sapiens	Residual Activity	%	123.0
	12217175	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217176	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	113.0	CHEMBL4070	Homo sapiens	Residual Activity	%	113.0
	12217177	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12217178	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12217179	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	111.0	CHEMBL4070	Homo sapiens	Residual Activity	%	111.0
	12217180	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	122.0	CHEMBL4070	Homo sapiens	Residual Activity	%	122.0
	12217181	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217182	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	116.0	CHEMBL4070	Homo sapiens	Residual Activity	%	116.0
	12217183	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	113.0	CHEMBL4070	Homo sapiens	Residual Activity	%	113.0
	12217184	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	56.0	CHEMBL4070	Homo sapiens	Residual Activity	%	56.0
	12217185	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217186	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217187	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	123.0	CHEMBL4070	Homo sapiens	Residual Activity	%	123.0
	12217188	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217189	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	129.0	CHEMBL4070	Homo sapiens	Residual Activity	%	129.0
	12217190	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217191	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	137.0	CHEMBL4070	Homo sapiens	Residual Activity	%	137.0
	12217192	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	128.0	CHEMBL4070	Homo sapiens	Residual Activity	%	128.0
	12217193	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	129.0	CHEMBL4070	Homo sapiens	Residual Activity	%	129.0
	12217194	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	105.0	CHEMBL4070	Homo sapiens	Residual Activity	%	105.0
	12217195	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	109.0	CHEMBL4070	Homo sapiens	Residual Activity	%	109.0
	12217196	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	126.0	CHEMBL4070	Homo sapiens	Residual Activity	%	126.0
	12217197	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	128.0	CHEMBL4070	Homo sapiens	Residual Activity	%	128.0
	12217198	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217199	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	129.0	CHEMBL4070	Homo sapiens	Residual Activity	%	129.0
	12217200	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	140.0	CHEMBL4070	Homo sapiens	Residual Activity	%	140.0
	12217201	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	130.0	CHEMBL4070	Homo sapiens	Residual Activity	%	130.0
	12217202	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	118.0	CHEMBL4070	Homo sapiens	Residual Activity	%	118.0
	12217203	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	12.0	CHEMBL4070	Homo sapiens	Residual Activity	%	12.0
	12217204	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	128.0	CHEMBL4070	Homo sapiens	Residual Activity	%	128.0
	12217205	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	129.0	CHEMBL4070	Homo sapiens	Residual Activity	%	129.0
	12217206	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217207	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217208	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	125.0	CHEMBL4070	Homo sapiens	Residual Activity	%	125.0
	12217209	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217210	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12217211	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12217212	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	117.0	CHEMBL4070	Homo sapiens	Residual Activity	%	117.0
	12217213	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217214	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	122.0	CHEMBL4070	Homo sapiens	Residual Activity	%	122.0
	12217215	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217216	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	115.0	CHEMBL4070	Homo sapiens	Residual Activity	%	115.0
	12217217	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12217218	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12217219	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	-12.0	CHEMBL4070	Homo sapiens	Residual Activity	%	-12.0
	12217220	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12217221	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	115.0	CHEMBL4070	Homo sapiens	Residual Activity	%	115.0
	12217222	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217223	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12217224	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217225	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	127.0	CHEMBL4070	Homo sapiens	Residual Activity	%	127.0
	12217226	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217227	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	52.0	CHEMBL4070	Homo sapiens	Residual Activity	%	52.0
	12217228	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	113.0	CHEMBL4070	Homo sapiens	Residual Activity	%	113.0
	12217229	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	131.0	CHEMBL4070	Homo sapiens	Residual Activity	%	131.0
	12217230	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	83.0	CHEMBL4070	Homo sapiens	Residual Activity	%	83.0
	12217231	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	112.0	CHEMBL4070	Homo sapiens	Residual Activity	%	112.0
	12217232	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12217233	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12217234	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	93.0	CHEMBL4070	Homo sapiens	Residual Activity	%	93.0
	12217235	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217236	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12217237	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	116.0	CHEMBL4070	Homo sapiens	Residual Activity	%	116.0
	12217238	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	122.0	CHEMBL4070	Homo sapiens	Residual Activity	%	122.0
	12217239	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217240	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217241	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	81.0	CHEMBL4070	Homo sapiens	Residual Activity	%	81.0
	12217242	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12217243	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	21.0	CHEMBL4070	Homo sapiens	Residual Activity	%	21.0
	12217244	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217245	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12217246	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12217247	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217248	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12217249	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217250	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217251	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	81.0	CHEMBL4070	Homo sapiens	Residual Activity	%	81.0
	12217252	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217253	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217254	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	63.0	CHEMBL4070	Homo sapiens	Residual Activity	%	63.0
	12217255	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217256	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217257	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217258	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12217259	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217260	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	112.0	CHEMBL4070	Homo sapiens	Residual Activity	%	112.0
	12217261	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12217262	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217263	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217264	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12217265	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12217266	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12217267	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	78.0	CHEMBL4070	Homo sapiens	Residual Activity	%	78.0
	12217268	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12217269	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217270	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217271	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	112.0	CHEMBL4070	Homo sapiens	Residual Activity	%	112.0
	12217272	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	109.0	CHEMBL4070	Homo sapiens	Residual Activity	%	109.0
	12217273	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217274	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12217275	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	46.0	CHEMBL4070	Homo sapiens	Residual Activity	%	46.0
	12217276	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217277	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217278	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217279	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	111.0	CHEMBL4070	Homo sapiens	Residual Activity	%	111.0
	12217280	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12217281	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217282	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	93.0	CHEMBL4070	Homo sapiens	Residual Activity	%	93.0
	12217283	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	59.0	CHEMBL4070	Homo sapiens	Residual Activity	%	59.0
	12217284	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12217285	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	111.0	CHEMBL4070	Homo sapiens	Residual Activity	%	111.0
	12217286	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12217287	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	111.0	CHEMBL4070	Homo sapiens	Residual Activity	%	111.0
	12217288	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12217289	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217290	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12217291	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217292	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217293	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	18.0	CHEMBL4070	Homo sapiens	Residual Activity	%	18.0
	12217294	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	26.0	CHEMBL4070	Homo sapiens	Residual Activity	%	26.0
	12217295	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12217296	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12217297	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217298	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	41.0	CHEMBL4070	Homo sapiens	Residual Activity	%	41.0
	12217299	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12217300	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	121.0	CHEMBL4070	Homo sapiens	Residual Activity	%	121.0
	12217301	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	88.0	CHEMBL4070	Homo sapiens	Residual Activity	%	88.0
	12217302	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	33.0	CHEMBL4070	Homo sapiens	Residual Activity	%	33.0
	12217303	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	103.0	CHEMBL4070	Homo sapiens	Residual Activity	%	103.0
	12217304	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	57.0	CHEMBL4070	Homo sapiens	Residual Activity	%	57.0
	12217305	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217306	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	109.0	CHEMBL4070	Homo sapiens	Residual Activity	%	109.0
	12217307	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	122.0	CHEMBL4070	Homo sapiens	Residual Activity	%	122.0
	12217308	CHEMBL2219000	Millipore: Percentage of residual kinase activity of CSNK2A2 at 1uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	116.0	CHEMBL4070	Homo sapiens	Residual Activity	%	116.0
	12217309	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	113.0	CHEMBL4070	Homo sapiens	Residual Activity	%	113.0
	12217310	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217311	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	103.0	CHEMBL4070	Homo sapiens	Residual Activity	%	103.0
	12217312	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12217313	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12217314	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	58.0	CHEMBL4070	Homo sapiens	Residual Activity	%	58.0
	12217315	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	80.0	CHEMBL4070	Homo sapiens	Residual Activity	%	80.0
	12217316	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217317	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12217318	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	89.0	CHEMBL4070	Homo sapiens	Residual Activity	%	89.0
	12217319	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12217320	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217321	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12217322	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	72.0	CHEMBL4070	Homo sapiens	Residual Activity	%	72.0
	12217323	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12217324	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	89.0	CHEMBL4070	Homo sapiens	Residual Activity	%	89.0
	12217325	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12217326	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12217327	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	91.0	CHEMBL4070	Homo sapiens	Residual Activity	%	91.0
	12217328	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	34.0	CHEMBL4070	Homo sapiens	Residual Activity	%	34.0
	12217329	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	98.0	CHEMBL4070	Homo sapiens	Residual Activity	%	98.0
	12217330	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12217331	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12217332	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12217333	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217334	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12217335	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	72.0	CHEMBL4070	Homo sapiens	Residual Activity	%	72.0
	12217336	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	38.0	CHEMBL4070	Homo sapiens	Residual Activity	%	38.0
	12217337	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	65.0	CHEMBL4070	Homo sapiens	Residual Activity	%	65.0
	12217338	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	91.0	CHEMBL4070	Homo sapiens	Residual Activity	%	91.0
	12217339	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	110.0	CHEMBL4070	Homo sapiens	Residual Activity	%	110.0
	12217340	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12217341	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12217342	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	5.0	CHEMBL4070	Homo sapiens	Residual Activity	%	5.0
	12217343	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	74.0	CHEMBL4070	Homo sapiens	Residual Activity	%	74.0
	12217344	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217345	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217346	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	105.0	CHEMBL4070	Homo sapiens	Residual Activity	%	105.0
	12217347	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	118.0	CHEMBL4070	Homo sapiens	Residual Activity	%	118.0
	12217348	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12217349	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12219707	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	93.0	CHEMBL4070	Homo sapiens	Residual Activity	%	93.0
	12219708	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12219709	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	36.0	CHEMBL4070	Homo sapiens	Residual Activity	%	36.0
	12219710	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	91.0	CHEMBL4070	Homo sapiens	Residual Activity	%	91.0
	12219711	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12219712	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	103.0	CHEMBL4070	Homo sapiens	Residual Activity	%	103.0
	12219713	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	74.0	CHEMBL4070	Homo sapiens	Residual Activity	%	74.0
	12219714	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	77.0	CHEMBL4070	Homo sapiens	Residual Activity	%	77.0
	12219715	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	79.0	CHEMBL4070	Homo sapiens	Residual Activity	%	79.0
	12219716	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	93.0	CHEMBL4070	Homo sapiens	Residual Activity	%	93.0
	12219717	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12219718	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	-1.0	CHEMBL4070	Homo sapiens	Residual Activity	%	-1.0
	12219719	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	98.0	CHEMBL4070	Homo sapiens	Residual Activity	%	98.0
	12219720	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12219721	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219722	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12219723	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	93.0	CHEMBL4070	Homo sapiens	Residual Activity	%	93.0
	12219724	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12219725	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	42.0	CHEMBL4070	Homo sapiens	Residual Activity	%	42.0
	12219726	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	32.0	CHEMBL4070	Homo sapiens	Residual Activity	%	32.0
	12219727	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12219728	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12219729	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12219730	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	111.0	CHEMBL4070	Homo sapiens	Residual Activity	%	111.0
	12219731	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12219732	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12219733	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12219734	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	-5.0	CHEMBL4070	Homo sapiens	Residual Activity	%	-5.0
	12219735	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12219736	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	119.0	CHEMBL4070	Homo sapiens	Residual Activity	%	119.0
	12219737	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	72.0	CHEMBL4070	Homo sapiens	Residual Activity	%	72.0
	12219738	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219739	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12219740	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	81.0	CHEMBL4070	Homo sapiens	Residual Activity	%	81.0
	12219741	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12219742	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	0.0	CHEMBL4070	Homo sapiens	Residual Activity	%	0.0
	12219743	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	47.0	CHEMBL4070	Homo sapiens	Residual Activity	%	47.0
	12219744	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	115.0	CHEMBL4070	Homo sapiens	Residual Activity	%	115.0
	12219745	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	85.0	CHEMBL4070	Homo sapiens	Residual Activity	%	85.0
	12219746	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12219747	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12219748	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12219749	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12219750	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12219751	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12219752	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	105.0	CHEMBL4070	Homo sapiens	Residual Activity	%	105.0
	12219753	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	105.0	CHEMBL4070	Homo sapiens	Residual Activity	%	105.0
	12219754	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219755	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	58.0	CHEMBL4070	Homo sapiens	Residual Activity	%	58.0
	12219756	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12219757	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219758	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	-2.0	CHEMBL4070	Homo sapiens	Residual Activity	%	-2.0
	12219759	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12219760	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	120.0	CHEMBL4070	Homo sapiens	Residual Activity	%	120.0
	12219761	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	109.0	CHEMBL4070	Homo sapiens	Residual Activity	%	109.0
	12219762	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219763	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	103.0	CHEMBL4070	Homo sapiens	Residual Activity	%	103.0
	12219764	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12219765	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	91.0	CHEMBL4070	Homo sapiens	Residual Activity	%	91.0
	12219766	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	21.0	CHEMBL4070	Homo sapiens	Residual Activity	%	21.0
	12219767	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12219768	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	106.0	CHEMBL4070	Homo sapiens	Residual Activity	%	106.0
	12219769	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	49.0	CHEMBL4070	Homo sapiens	Residual Activity	%	49.0
	12219770	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	29.0	CHEMBL4070	Homo sapiens	Residual Activity	%	29.0
	12219771	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12219772	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	65.0	CHEMBL4070	Homo sapiens	Residual Activity	%	65.0
	12219773	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	85.0	CHEMBL4070	Homo sapiens	Residual Activity	%	85.0
	12219774	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	90.0	CHEMBL4070	Homo sapiens	Residual Activity	%	90.0
	12219775	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219776	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	114.0	CHEMBL4070	Homo sapiens	Residual Activity	%	114.0
	12219777	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219778	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	86.0	CHEMBL4070	Homo sapiens	Residual Activity	%	86.0
	12219779	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	98.0	CHEMBL4070	Homo sapiens	Residual Activity	%	98.0
	12219780	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	102.0	CHEMBL4070	Homo sapiens	Residual Activity	%	102.0
	12219781	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219782	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	18.0	CHEMBL4070	Homo sapiens	Residual Activity	%	18.0
	12219783	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	95.0	CHEMBL4070	Homo sapiens	Residual Activity	%	95.0
	12219784	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	60.0	CHEMBL4070	Homo sapiens	Residual Activity	%	60.0
	12219785	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12219786	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	87.0	CHEMBL4070	Homo sapiens	Residual Activity	%	87.0
	12219787	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	71.0	CHEMBL4070	Homo sapiens	Residual Activity	%	71.0
	12219788	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	103.0	CHEMBL4070	Homo sapiens	Residual Activity	%	103.0
	12219789	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12219790	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	3.0	CHEMBL4070	Homo sapiens	Residual Activity	%	3.0
	12219791	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	101.0	CHEMBL4070	Homo sapiens	Residual Activity	%	101.0
	12219792	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	112.0	CHEMBL4070	Homo sapiens	Residual Activity	%	112.0
	12219793	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	99.0	CHEMBL4070	Homo sapiens	Residual Activity	%	99.0
	12219794	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12219795	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	62.0	CHEMBL4070	Homo sapiens	Residual Activity	%	62.0
	12219796	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	107.0	CHEMBL4070	Homo sapiens	Residual Activity	%	107.0
	12219797	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219798	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	18.0	CHEMBL4070	Homo sapiens	Residual Activity	%	18.0
	12219799	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	98.0	CHEMBL4070	Homo sapiens	Residual Activity	%	98.0
	12219800	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219801	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	96.0	CHEMBL4070	Homo sapiens	Residual Activity	%	96.0
	12219802	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	64.0	CHEMBL4070	Homo sapiens	Residual Activity	%	64.0
	12219803	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	75.0	CHEMBL4070	Homo sapiens	Residual Activity	%	75.0
	12219804	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	57.0	CHEMBL4070	Homo sapiens	Residual Activity	%	57.0
	12219805	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	65.0	CHEMBL4070	Homo sapiens	Residual Activity	%	65.0
	12219806	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219807	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	108.0	CHEMBL4070	Homo sapiens	Residual Activity	%	108.0
	12219808	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	4.0	CHEMBL4070	Homo sapiens	Residual Activity	%	4.0
	12219809	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	1.0	CHEMBL4070	Homo sapiens	Residual Activity	%	1.0
	12219810	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	104.0	CHEMBL4070	Homo sapiens	Residual Activity	%	104.0
	12219811	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	94.0	CHEMBL4070	Homo sapiens	Residual Activity	%	94.0
	12219812	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	89.0	CHEMBL4070	Homo sapiens	Residual Activity	%	89.0
	12219813	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	15.0	CHEMBL4070	Homo sapiens	Residual Activity	%	15.0
	12219814	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	73.0	CHEMBL4070	Homo sapiens	Residual Activity	%	73.0
	12219815	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12219816	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	32.0	CHEMBL4070	Homo sapiens	Residual Activity	%	32.0
	12219817	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	5.0	CHEMBL4070	Homo sapiens	Residual Activity	%	5.0
	12219818	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	73.0	CHEMBL4070	Homo sapiens	Residual Activity	%	73.0
	12219819	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	52.0	CHEMBL4070	Homo sapiens	Residual Activity	%	52.0
	12219820	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	92.0	CHEMBL4070	Homo sapiens	Residual Activity	%	92.0
	12219821	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12219822	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	97.0	CHEMBL4070	Homo sapiens	Residual Activity	%	97.0
	12219823	CHEMBL2219001	Millipore: Percentage of residual kinase activity of CSNK2A2 at 10uM relative to control. Control inhibitor: Jnk Inhibitor II at 100.0uM. Buffer: 20 mM HEPES pH 7.6, 0.15 M NaCl, 0.1 mM EDTA, 5 mM DTT, 0.1% Triton X-100	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	100.0	CHEMBL4070	Homo sapiens	Residual Activity	%	100.0
	12657933	CHEMBL2330174	Inhibition of CK2alpha2 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	B	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21		CHEMBL58	=	Activity	%	81.8	CHEMBL4070	Homo sapiens	Activity	%	81.8
	12679723	CHEMBL2345833	Inhibition of CSNK2A2 (unknown origin) at 1 uM	B	Cc1ccc(-c2ccc3ncc4c(c3n2)n(C2CCN(C(=O)[C@H](C)O)CC2)c(=O)n4C)cn1		CHEMBL2331664	=	Inhibition	%	3.0	CHEMBL4070	Homo sapiens	INH	%	3.0
	12728870	CHEMBL2349953	Inhibition of CK2 alpha2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	103.0	CHEMBL4070	Homo sapiens	Activity	%	103.0
	12730012	CHEMBL2353888	Inhibition of CK2 alpha2 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	105.0	CHEMBL4070	Homo sapiens	Activity	%	105.0
	12730260	CHEMBL2349953	Inhibition of CK2 alpha2 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	12730892	CHEMBL2349820	Inhibition of CK2a2 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	53.0	CHEMBL4070	Homo sapiens	Activity	%	53.0
Not Active	13328775	CHEMBL2388498	Inhibition of CSNK2A2 (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
	13375899	CHEMBL2405307	Inhibition of CK2alpha2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	3.0	CHEMBL4070	Homo sapiens	INH	%	3.0
	13439875	CHEMBL2428165	Competitive binding affinity to CSNK2A2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	13445397	CHEMBL2428165	Competitive binding affinity to CSNK2A2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	98.0	CHEMBL4070	Homo sapiens	INH	%	98.0
	13448440	CHEMBL2428165	Competitive binding affinity to CSNK2A2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	86.0	CHEMBL4070	Homo sapiens	INH	%	86.0
	13451695	CHEMBL2428165	Competitive binding affinity to CSNK2A2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	13872178	CHEMBL3101930	Inhibition of human CK2a2 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	28.0	CHEMBL4070	Homo sapiens	Activity	%	28.0
	13879302	CHEMBL3106920	Inhibition of N-terminal 6 X His-tagged recombinant human full length Casein Kinase 2 alpha subunit expressed in Sf21 insect cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by fluorescence-based assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN		CHEMBL3103192	<	IC50	nM	3000.0	CHEMBL4070	Homo sapiens	IC50	mM	0.003
	13879304	CHEMBL3106920	Inhibition of N-terminal 6 X His-tagged recombinant human full length Casein Kinase 2 alpha subunit expressed in Sf21 insect cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by fluorescence-based assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN(C)C		CHEMBL3103191	<	IC50	nM	4000.0	CHEMBL4070	Homo sapiens	IC50	mM	0.004
	13918706	CHEMBL3118226	Inhibition of human CK2alpha2	B	C[C@H](Nc1nc(Nc2cn(C)cn2)c2cc[nH]c2n1)c1ncc(F)cn1		CHEMBL3116050	=	IC50	nM	2.7	CHEMBL4070	Homo sapiens	IC50	uM	0.0027
	13954700	CHEMBL3130944	Inhibition of human CK2-alpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	91.0	CHEMBL4070	Homo sapiens	Activity	%	91.0
	13954744	CHEMBL3130944	Inhibition of human CK2-alpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	74.0	CHEMBL4070	Homo sapiens	Activity	%	74.0
	13954766	CHEMBL3130944	Inhibition of human CK2-alpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	59.0	CHEMBL4070	Homo sapiens	Activity	%	59.0
	14582468	CHEMBL3240428	Inhibition of human CK2alpha2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	99.0	CHEMBL4070	Homo sapiens	Activity	%	99.0
Active	15122489	CHEMBL3367677	Inhibition of recombinant human CK2alpha assessed as inhibition of phosphorylation of GST-CS at 10 uM by Coomassie brilliant blue staining based autoradiography	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Dose-dependent effect	15126923	CHEMBL3367945	Inhibition of PKCK2alpha (unknown origin) overexpressed in TE2 cells assessed as inhibition of phosphorylation of GST-CS after 24 hrs by in vitro kinase assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Dose-dependent effect	15126924	CHEMBL3367945	Inhibition of PKCK2alpha (unknown origin) overexpressed in TE2 cells assessed as inhibition of phosphorylation of GST-CS after 24 hrs by in vitro kinase assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Dose-dependent effect	15126925	CHEMBL3367946	Inhibition of PKCK2alpha (unknown origin) overexpressed in TE2 cells assessed as inhibition of phosphorylation of GST-CS	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Active	15126948	CHEMBL3367677	Inhibition of recombinant human CK2alpha assessed as inhibition of phosphorylation of GST-CS at 10 uM by Coomassie brilliant blue staining based autoradiography	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3cc(O)c(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331446		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Active	15127030	CHEMBL3367944	Inhibition of recombinant human CK2alpha assessed as inhibition of phosphorylation of GST-CS by Coomassie brilliant blue staining based autoradiography	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Dose-dependent effect	15127031	CHEMBL3367946	Inhibition of PKCK2alpha (unknown origin) overexpressed in TE2 cells assessed as inhibition of phosphorylation of GST-CS	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
	15236106	CHEMBL3424701	Inhibition of human Casein kinase 2 alpha prime polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@H](C)N		CHEMBL1835439	=	Activity	%	98.0	CHEMBL4070	Homo sapiens	Activity	%	98.0
	15236132	CHEMBL3424701	Inhibition of human Casein kinase 2 alpha prime polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)[C@@H](C)O		CHEMBL3422705	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	15236166	CHEMBL3424701	Inhibition of human Casein kinase 2 alpha prime polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CC(C)C		CHEMBL3422697	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	15236190	CHEMBL3424701	Inhibition of human Casein kinase 2 alpha prime polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCC[C@@H](O)[C@@H](N)Cc1ccccc1		CHEMBL3422700	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	15756052	CHEMBL3632319	Inhibition of CK2alpha2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	39.82	CHEMBL4070	Homo sapiens	INH	%	39.82
	15757008	CHEMBL3632319	Inhibition of CK2alpha2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1	Outside typical range	CHEMBL166031	=	Inhibition	%	-10.31	CHEMBL4070	Homo sapiens	INH	%	-10.31
	15758670	CHEMBL3632319	Inhibition of CK2alpha2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	-7.82	CHEMBL4070	Homo sapiens	INH	%	-7.82
279086	16258789	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	C=Cc1cc(C#N)cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1Cl		CHEMBL3699294	=	IC50	nM	0.16	CHEMBL4070	Homo sapiens	IC50	nM	0.16
279038	16258948	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NCC(F)(F)F)CC2)c1		CHEMBL3699246	=	IC50	nM	20.89	CHEMBL4070	Homo sapiens	IC50	nM	20.89
279053	16259710	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OC		CHEMBL3699261	=	IC50	nM	61.21	CHEMBL4070	Homo sapiens	IC50	nM	61.21
279091	16260884	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC1(C)CC(Oc2cc(F)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC(C)(C)N1		CHEMBL3699299	=	IC50	nM	16.04	CHEMBL4070	Homo sapiens	IC50	nM	16.04
279028	16261845	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC2(C1)CN(c1cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c1Cl)C2		CHEMBL3699236	=	IC50	nM	0.87	CHEMBL4070	Homo sapiens	IC50	nM	0.87
257628	16269749	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccnc(F)c3)cc(C(=O)N[C@H]3CC[C@H](O)CC3)c12		CHEMBL3681193	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
279065	16269826	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCN(C5(CS(=O)(=O)c6ccccc6)COC5)CC4)c3Cl)nn12		CHEMBL3699273	=	IC50	nM	3.16	CHEMBL4070	Homo sapiens	IC50	nM	3.16
257644	16269884	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CCOC3)c3c(N)ncnn23)ccn1		CHEMBL3681206	=	IC50	nM	2.2	CHEMBL4070	Homo sapiens	IC50	nM	2.2
279032	16272362	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N1CCC(N2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)CC1		CHEMBL3699240	=	IC50	nM	0.93	CHEMBL4070	Homo sapiens	IC50	nM	0.93
257630	16272414	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CNCCCNC(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681196	=	IC50	nM	380.0	CHEMBL4070	Homo sapiens	IC50	nM	380.0
279033	16273933	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CS(=O)(=O)CCN1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699241	=	IC50	nM	0.99	CHEMBL4070	Homo sapiens	IC50	nM	0.99
257654	16273950	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)ccc1C(N)=O		CHEMBL3681216	=	IC50	nM	790.0	CHEMBL4070	Homo sapiens	IC50	nM	790.0
279045	16274493	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC1CCN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699253	=	IC50	nM	0.31	CHEMBL4070	Homo sapiens	IC50	nM	0.31
257631	16274820	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)OC(=O)NCCCCCNC(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681221	=	IC50	nM	60.0	CHEMBL4070	Homo sapiens	IC50	nM	60.0
257639	16275326	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@@H]3CCCN(C(=O)C4(N)CC4)C3)c3c(N)ncnn23)ccn1		CHEMBL3681201	=	IC50	nM	2.5	CHEMBL4070	Homo sapiens	IC50	nM	2.5
257634	16276272	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)N[C@H]3CC[C@@H](O)CC3)c12		CHEMBL3681220	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
257629	16276489	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCOC(=O)NC1CCC(NC(=O)c2cc(-c3ccnc(OC)c3)n3ncnc(N)c23)CC1		CHEMBL3681194	=	IC50	nM	2.8	CHEMBL4070	Homo sapiens	IC50	nM	2.8
257646	16277066	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C(C)(C)CN4CCCC4)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681208	=	IC50	nM	3.7	CHEMBL4070	Homo sapiens	IC50	nM	3.7
279056	16278427	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(C3CC(CO)(CO)C3)CC2)c1		CHEMBL3699264	=	IC50	nM	0.76	CHEMBL4070	Homo sapiens	IC50	nM	0.76
279070	16278599	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCN(C5COC5)CC(F)C4)c3Cl)nn12		CHEMBL3699278	=	IC50	nM	0.21	CHEMBL4070	Homo sapiens	IC50	nM	0.21
257633	16280415	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCOC(=O)N[C@H]1CC[C@H](NC(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681195	=	IC50	nM	70.0	CHEMBL4070	Homo sapiens	IC50	nM	70.0
279081	16280712	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(Nc3nc(C)n(C)n3)nc(Nc3ccc4c(c3)c(C#N)nn4C)nn12		CHEMBL3699289	=	IC50	nM	0.03	CHEMBL4070	Homo sapiens	IC50	nM	0.03
279058	16281460	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(=O)N1CCC(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699266	=	IC50	nM	0.16	CHEMBL4070	Homo sapiens	IC50	nM	0.16
279083	16282903	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C[C@H](C)O)CC2)nn2c(C#N)cnc12		CHEMBL3699291	=	IC50	nM	0.27	CHEMBL4070	Homo sapiens	IC50	nM	0.27
257638	16284967	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C4(CN)CC4)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681200	=	IC50	nM	3.6	CHEMBL4070	Homo sapiens	IC50	nM	3.6
279072	16287396	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(=O)N1CC(N2CCC(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699280	=	IC50	nM	0.25	CHEMBL4070	Homo sapiens	IC50	nM	0.25
279064	16290208	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCN(C5(C#N)COC5)CC4)c3Cl)nn12		CHEMBL3699272	=	IC50	nM	3.21	CHEMBL4070	Homo sapiens	IC50	nM	3.21
257648	16290645	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681210	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
279095	16290985	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CCN(CC(F)F)CC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699303	=	IC50	nM	0.74	CHEMBL4070	Homo sapiens	IC50	nM	0.74
279073	16293420	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CC[C@@H](NC(=O)OC)[C@H](O)C4)c3Cl)nn12		CHEMBL3699281	=	IC50	nM	2.95	CHEMBL4070	Homo sapiens	IC50	nM	2.95
257640	16294996	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C(C)(C)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681202	=	IC50	nM	2.7	CHEMBL4070	Homo sapiens	IC50	nM	2.7
279068	16295872	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OP(=O)(O)O		CHEMBL3699276	=	IC50	nM	0.09	CHEMBL4070	Homo sapiens	IC50	nM	0.09
279090	16296083	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(F)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC1(C)C		CHEMBL3699298	=	IC50	nM	19.71	CHEMBL4070	Homo sapiens	IC50	nM	19.71
279092	16296694	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(F)c(C#N)cc2Nc2nc(NC3CC3)c3ncc(C#N)n3n2)CC1(C)C		CHEMBL3699300	=	IC50	nM	1.43	CHEMBL4070	Homo sapiens	IC50	nM	1.43
257652	16296728	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)N(CC1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1)C(=O)O		CHEMBL3681214	=	IC50	nM	750.0	CHEMBL4070	Homo sapiens	IC50	nM	750.0
279078	16299238	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CC[C@@H]4[C@@H](C3)OCCN4C3COC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699286	=	IC50	nM	0.52	CHEMBL4070	Homo sapiens	IC50	nM	0.52
257649	16299722	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)C(OC(N)=O)C1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)C1		CHEMBL3681211	=	IC50	nM	560.0	CHEMBL4070	Homo sapiens	IC50	nM	560.0
279060	16299937	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@H]1CN(c2cc(C(F)F)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OC		CHEMBL3699268	=	IC50	nM	1.17	CHEMBL4070	Homo sapiens	IC50	nM	1.17
257657	16300514	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccnc(CCO)c3)cc(C(=O)NC3CCC(N)CC3)c12		CHEMBL3681219	=	IC50	nM	330.0	CHEMBL4070	Homo sapiens	IC50	nM	330.0
279087	16301593	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(CO)c(Cl)c(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1		CHEMBL3699295	=	IC50	nM	0.11	CHEMBL4070	Homo sapiens	IC50	nM	0.11
279076	16302682	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(C4CCNCC4)c3Cl)nn12		CHEMBL3699284	=	IC50	nM	0.76	CHEMBL4070	Homo sapiens	IC50	nM	0.76
257642	16304590	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)NC[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681204	=	IC50	nM	3.2	CHEMBL4070	Homo sapiens	IC50	nM	3.2
279044	16305438	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CS(=O)(=O)C1CCN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699252	=	IC50	nM	0.11	CHEMBL4070	Homo sapiens	IC50	nM	0.11
279075	16305902	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cccc(C#N)n3)nn12		CHEMBL3699283	=	IC50	nM	81.62	CHEMBL4070	Homo sapiens	IC50	nM	81.62
279057	16307558	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(CCC(F)(F)F)CC2)c1		CHEMBL3699265	=	IC50	nM	2.05	CHEMBL4070	Homo sapiens	IC50	nM	2.05
279080	16310508	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C(F)F)cc(N4CCN(C5COC5)CC4)c3Cl)nn12		CHEMBL3699288	=	IC50	nM	4.53	CHEMBL4070	Homo sapiens	IC50	nM	4.53
279077	16310558	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CCC(NC[C@@H](C)O)CC4)c3Cl)nn12		CHEMBL3699285	=	IC50	nM	0.61	CHEMBL4070	Homo sapiens	IC50	nM	0.61
279047	16310802	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CC(N3CC(O)C3)C2)c1		CHEMBL3699255	=	IC50	nM	0.27	CHEMBL4070	Homo sapiens	IC50	nM	0.27
257656	16312104	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)Oc1cc(-c2cc(C(=O)NC3CCC(N)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681218	=	IC50	nM	700.0	CHEMBL4070	Homo sapiens	IC50	nM	700.0
279029	16313041	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(NN2CCOCC2)c1		CHEMBL3699237	=	IC50	nM	0.11	CHEMBL4070	Homo sapiens	IC50	nM	0.11
279088	16313897	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CCN(C4COC4)CC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699296	=	IC50	nM	0.23	CHEMBL4070	Homo sapiens	IC50	nM	0.23
279061	16316976	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC(N2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699269	=	IC50	nM	0.47	CHEMBL4070	Homo sapiens	IC50	nM	0.47
279037	16317701	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NC3CC(C#N)C3)CC2)c1		CHEMBL3699245	=	IC50	nM	1.53	CHEMBL4070	Homo sapiens	IC50	nM	1.53
257637	16317900	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)CC(C)(C)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681199	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
257651	16318537	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	NCC1CCCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)C1		CHEMBL3681213	=	IC50	nM	670.0	CHEMBL4070	Homo sapiens	IC50	nM	670.0
279089	16318735	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(NC2CCN(C3COC3)CC2)c1		CHEMBL3699297	=	IC50	nM	0.82	CHEMBL4070	Homo sapiens	IC50	nM	0.82
279094	16319019	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(OC2CCNCC2)cc1F		CHEMBL3699302	=	IC50	nM	2.75	CHEMBL4070	Homo sapiens	IC50	nM	2.75
279031	16319238	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	C[C@@H](O)CN1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699239	=	IC50	nM	0.28	CHEMBL4070	Homo sapiens	IC50	nM	0.28
279079	16319400	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CC(N5CCN(C)CC5)C4)c3F)nn12		CHEMBL3699287	=	IC50	nM	0.61	CHEMBL4070	Homo sapiens	IC50	nM	0.61
279074	16319820	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CC[C@H](NC(=O)OC)[C@@H](O)C4)c3Cl)nn12		CHEMBL3699282	=	IC50	nM	0.13	CHEMBL4070	Homo sapiens	IC50	nM	0.13
279069	16321414	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@@H]1F		CHEMBL3699277	=	IC50	nM	0.45	CHEMBL4070	Homo sapiens	IC50	nM	0.45
279084	16323386	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C[C@@H](C)O)CC2)nn2c(C#N)cnc12		CHEMBL3699292	=	IC50	nM	0.21	CHEMBL4070	Homo sapiens	IC50	nM	0.21
279035	16323621	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(C)NC1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699243	=	IC50	nM	15.53	CHEMBL4070	Homo sapiens	IC50	nM	15.53
279052	16324520	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CCN(CC(=O)N[C@@H]2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C[C@H]2O)CC1		CHEMBL3699260	=	IC50	nM	0.64	CHEMBL4070	Homo sapiens	IC50	nM	0.64
279096	16324787	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3nc(C#N)ncc3Cl)nn12		CHEMBL3699304	=	IC50	nM	5.1	CHEMBL4070	Homo sapiens	IC50	nM	5.1
279085	16326639	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C3COC3)CC2)nn2c(C#N)cnc12		CHEMBL3699293	=	IC50	nM	0.94	CHEMBL4070	Homo sapiens	IC50	nM	0.94
279027	16327514	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(O)C2)c1		CHEMBL3699235	=	IC50	nM	0.07	CHEMBL4070	Homo sapiens	IC50	nM	0.07
279071	16328029	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCN(C5COC5)C(C(=O)N5CCOCC5)C4)c3Cl)nn12		CHEMBL3699279	=	IC50	nM	1.32	CHEMBL4070	Homo sapiens	IC50	nM	1.32
257632	16328746	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(=O)NC1CCC(NC(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681197	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
257647	16329508	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681209	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
279026	16331250	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	Cn1nc(C#N)c2cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)ccc21		CHEMBL3699234	=	IC50	nM	0.09	CHEMBL4070	Homo sapiens	IC50	nM	0.09
279049	16331616	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@@H]1O		CHEMBL3699257	=	IC50	nM	0.35	CHEMBL4070	Homo sapiens	IC50	nM	0.35
279040	16331964	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(N(CC3CC3)CC3CC3)CC2)c1		CHEMBL3699248	=	IC50	nM	85.66	CHEMBL4070	Homo sapiens	IC50	nM	85.66
279082	16332004	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(Nc3nc(C)n(C)n3)nc(Nc3ccc4c(c3)c(C#N)nn4C[C@@H](C)O)nn12		CHEMBL3699290	=	IC50	nM	2.47	CHEMBL4070	Homo sapiens	IC50	nM	2.47
279030	16332078	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCN(C3CCOC3)CC2)c1		CHEMBL3699238	=	IC50	nM	0.2	CHEMBL4070	Homo sapiens	IC50	nM	0.2
279041	16332857	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COCCNC1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699249	=	IC50	nM	24.95	CHEMBL4070	Homo sapiens	IC50	nM	24.95
279054	16333134	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC=C(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699262	=	IC50	nM	0.23	CHEMBL4070	Homo sapiens	IC50	nM	0.23
257635	16334435	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)NCCc3ccccn3)c12		CHEMBL3681222	=	IC50	nM	50.0	CHEMBL4070	Homo sapiens	IC50	nM	50.0
279051	16334555	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CC[C@@H](NC(=O)OC3COC3)[C@H](O)C2)c1		CHEMBL3699259	=	IC50	nM	0.26	CHEMBL4070	Homo sapiens	IC50	nM	0.26
279046	16335018	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C[C@H]1C		CHEMBL3699254	=	IC50	nM	0.49	CHEMBL4070	Homo sapiens	IC50	nM	0.49
257653	16335188	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CN(CCCN)C(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681215	=	IC50	nM	810.0	CHEMBL4070	Homo sapiens	IC50	nM	810.0
279093	16335697	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(OC3CC(C)(C)N(C)C(C)(C)C3)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC1(C)C		CHEMBL3699301	=	IC50	nM	46.59	CHEMBL4070	Homo sapiens	IC50	nM	46.59
279063	16335775	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC(CN2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699271	=	IC50	nM	4.72	CHEMBL4070	Homo sapiens	IC50	nM	4.72
257641	16337152	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@@H](CO)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681203	=	IC50	nM	3.4	CHEMBL4070	Homo sapiens	IC50	nM	3.4
257650	16337845	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N3CCC(O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681212	=	IC50	nM	560.0	CHEMBL4070	Homo sapiens	IC50	nM	560.0
279055	16339539	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(C)(C)[Si](C)(C)O[C@@H]1CC(N2CCC(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)CC[C@H]1N		CHEMBL3699263	=	IC50	nM	8.18	CHEMBL4070	Homo sapiens	IC50	nM	8.18
279048	16340215	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1O		CHEMBL3699256	=	IC50	nM	0.27	CHEMBL4070	Homo sapiens	IC50	nM	0.27
279042	16341766	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(N[C@H]3C[C@@H](O)C3)CC2)c1		CHEMBL3699250	=	IC50	nM	0.54	CHEMBL4070	Homo sapiens	IC50	nM	0.54
279050	16342522	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COCCOC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1O		CHEMBL3699258	=	IC50	nM	0.49	CHEMBL4070	Homo sapiens	IC50	nM	0.49
257655	16342845	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	NC(=O)c1cccc(-c2cc(C(=O)N[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)c1		CHEMBL3681217	=	IC50	nM	1000.0	CHEMBL4070	Homo sapiens	IC50	nM	1000.0
279066	16345143	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC1(N2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)COC1		CHEMBL3699274	=	IC50	nM	0.75	CHEMBL4070	Homo sapiens	IC50	nM	0.75
279062	16347040	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC1CN(C2CN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699270	=	IC50	nM	5.96	CHEMBL4070	Homo sapiens	IC50	nM	5.96
279059	16348107	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(C(=O)OC3COC3)CC2)c1		CHEMBL3699267	=	IC50	nM	0.27	CHEMBL4070	Homo sapiens	IC50	nM	0.27
279043	16351183	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CN(C2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C[C@@H]1C		CHEMBL3699251	=	IC50	nM	1.61	CHEMBL4070	Homo sapiens	IC50	nM	1.61
257645	16351273	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCN1CCCC1CNC(=O)[C@H]1CC[C@H](NC(=O)c2cc(-c3ccnc(OC)c3)n3ncnc(N)c23)CC1		CHEMBL3681207	=	IC50	nM	3.9	CHEMBL4070	Homo sapiens	IC50	nM	3.9
279036	16353333	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NC3CCS(=O)(=O)C3)CC2)c1		CHEMBL3699244	=	IC50	nM	0.15	CHEMBL4070	Homo sapiens	IC50	nM	0.15
279067	16353756	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCC(C5COC5)CC4)c3Cl)nn12		CHEMBL3699275	=	IC50	nM	3.01	CHEMBL4070	Homo sapiens	IC50	nM	3.01
279039	16355167	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NCC(F)F)CC2)c1		CHEMBL3699247	=	IC50	nM	153.6	CHEMBL4070	Homo sapiens	IC50	nM	153.6
279034	16356087	CHEMBL3707628	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCC(NC5CC(F)(F)C5)CC4)c3Cl)nn12		CHEMBL3699242	=	IC50	nM	0.7	CHEMBL4070	Homo sapiens	IC50	nM	0.7
257643	16356152	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](C(=O)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681205	=	IC50	nM	3.6	CHEMBL4070	Homo sapiens	IC50	nM	3.6
257636	16356392	CHEMBL3707831	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)NC3CCOCC3)c12		CHEMBL3681198	=	IC50	nM	60.0	CHEMBL4070	Homo sapiens	IC50	nM	60.0
	16362982	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3715306	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362983	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3[nH]ncc3c2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3718475	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362984	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]ncc4c3)[nH]c2c1-c1ccccn1		CHEMBL3717400	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362985	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OC(F)(F)O3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715197	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362986	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCNc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3717072	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362987	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CC(=O)Nc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3716838	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362988	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c2c1-c1ccccn1		CHEMBL3715729	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362989	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3717173	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362990	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccn1		CHEMBL3716003	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362991	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3718311	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362992	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3716004	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362993	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=C(NCc1ccccc1)c1cnn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3716028	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362994	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CN(Cc1ccccc1)C(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3719350	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362995	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccc1		CHEMBL3717434	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362996	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c2c1-c1ccccc1		CHEMBL3719372	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362997	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3716797	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362998	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccccc1-c1cc(=O)n2ncc(-c3ccccn3)c2[nH]1		CHEMBL3716796	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16362999	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(Cc3ccccc3)cnn12		CHEMBL3718461	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363000	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3719099	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363001	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3717372	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363002	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3718933	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363003	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3714911	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363004	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccc3)c(O)nn12		CHEMBL3715280	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363005	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(Cl)c(Cl)c2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3714937	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363006	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715245	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363007	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3719218	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363008	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3nc(O)c(-c4ccccn4)c3[nH]2)c(OC)c1		CHEMBL3718915	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363009	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc2c(c1)CCc1c-2[nH]c2c(-c3ccccn3)cnn2c1=O		CHEMBL3719187	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363010	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccc(N4CCCC4)nc3)cnn12		CHEMBL3714936	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363011	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn12		CHEMBL3718125	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363012	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1c2c([nH]c3c(-c4ccccn4)cnn13)-c1ccccc1CC2		CHEMBL3715277	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363013	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	NC(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3715534	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363014	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	N#Cc1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3719132	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363015	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1OC		CHEMBL3716419	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363016	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3716856	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363017	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3715734	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363018	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3715727	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363019	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3718504	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363020	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3716831	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363021	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3cc[nH]c3c2)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3715239	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363022	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cccc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCCO5)[nH]c23)c1		CHEMBL3715752	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363023	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccc(F)cc1		CHEMBL3716034	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363024	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccccn2)[nH]c2c(-c3ccc(F)cc3)cnn12		CHEMBL3715012	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363025	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3cccnc3)[nH]c2c1-c1ccc(F)cc1		CHEMBL3716356	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363026	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3718717	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363027	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1cccc(Cl)c1		CHEMBL3718072	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363028	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4ncccc4c3)[nH]c2c1Cc1ccccc1		CHEMBL3715308	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363029	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4cccnc4)c3[nH]2)cc1		CHEMBL3718928	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363030	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCc1c(C)nn2c(=O)cc(-c3ccc(OC)cc3)[nH]c12		CHEMBL3716589	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363031	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4cc[nH]c4c3)[nH]c2c1Cc1ccccc1		CHEMBL3717516	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363032	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1cccnc1		CHEMBL3717739	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363033	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccn1		CHEMBL3714956	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363034	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3718833	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363035	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3717141	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363036	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3715111	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363037	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3717873	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363038	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2cc3ccccc3o2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715315	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363089	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccc1		CHEMBL3717800	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363138	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3717062	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363725	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3F)[nH]c2c1-c1ccccn1		CHEMBL3715384	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363726	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3ncccc3F)cnn12		CHEMBL3719038	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363727	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc(F)cc3)[nH]c2c1-c1ccccn1		CHEMBL3716009	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363728	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccn1		CHEMBL3719303	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363729	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3717777	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363730	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c12		CHEMBL3716353	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363731	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]ncc4c3)[nH]c12		CHEMBL3717256	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363732	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccc1		CHEMBL3716608	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363733	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccn1		CHEMBL3718202	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363734	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CC(=O)Nc1nn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c2c1-c1ccccn1		CHEMBL3718184	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363735	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1ccccn1		CHEMBL3715232	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363736	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3714786	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363737	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1cnn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c12		CHEMBL3715094	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363738	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccc(Cl)cc1		CHEMBL3716007	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363739	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3ccc(Cl)cc3)cnn12		CHEMBL3715305	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363740	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c12		CHEMBL3718786	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363741	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]nc(C)c4c3)[nH]c12		CHEMBL3715395	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363742	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3717588	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363743	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCCNC(=O)c1c(O)nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c12		CHEMBL3715749	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363744	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1c(-c2cc(=O)n3nc(N)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3718154	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363745	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1c(-c2cc(=O)n3nc(O)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3718721	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363746	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1c(-c2cc(=O)n3nc(C)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3716739	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363747	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc2[nH]nnc2cc1-c1cc(=O)n2nc(N)c(-c3ccccn3)c2[nH]1		CHEMBL3717392	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363748	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1c(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)ccc2[nH]nnc12		CHEMBL3715940	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363749	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2cc3nn[nH]c3cc2F)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715630	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363750	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(-c3ncco3)cc2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715461	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363751	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	N#Cc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1		CHEMBL3716508	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363752	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccccc4Cl)c3[nH]2)cc1		CHEMBL3718613	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363753	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccc(N4CCCCC4)nc3)cnn12		CHEMBL3716458	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363754	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3cccc(F)c3)cnn12		CHEMBL3716381	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363755	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccc(F)cc4)c3[nH]2)cc1		CHEMBL3717491	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363756	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)CCO4)[nH]c2c1-c1ccccc1		CHEMBL3717687	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363757	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1		CHEMBL3716647	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363758	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717429	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363759	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1Cc1ccccc1		CHEMBL3719324	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363760	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc(OC(C)C)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717587	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363761	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)c1		CHEMBL3715675	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363762	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COC(=O)c1ccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)cc1		CHEMBL3718477	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363763	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc(C(N)=O)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3718878	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363764	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc(C(F)(F)F)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717637	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363765	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccccc4)c3[nH]2)cc1OC		CHEMBL3715144	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16363766	CHEMBL3720977	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)cc1OC		CHEMBL3718262	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365741	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ncco1		CHEMBL3715226	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365742	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)o1		CHEMBL3718846	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365743	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1coc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)n1		CHEMBL3717312	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365744	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5[nH]nnc5c4)[nH]c23)o1		CHEMBL3715057	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365745	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5nc(C)co5)c4[nH]3)ccc21		CHEMBL3718043	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365746	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCc1coc(-c2cnn3c(=O)cc(-c4ccc5[nH]nnc5c4)[nH]c23)n1		CHEMBL3715959	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365747	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCc1coc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)n1		CHEMBL3717585	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365748	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncc(C)o4)c3[nH]2)ccc1Cl		CHEMBL3714819	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365749	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4nc(C)co4)c3[nH]2)ccc1Cl		CHEMBL3717056	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365750	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncco4)c3[nH]2)ccc1Cl		CHEMBL3716116	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365751	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5ncco5)c4[nH]3)ccc21		CHEMBL3717677	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365752	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCOc1cc(-c2cc(=O)n3ncc(-c4nc(C)co4)c3[nH]2)ccc1Cl		CHEMBL3716329	>	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365753	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc3[nH]ncc3c2)[nH]c2c(-c3ncco3)cnn12		CHEMBL3717303	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365754	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5[nH]ncc5c4)[nH]c23)o1		CHEMBL3717895	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365755	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCc1cnc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5CC)c4)[nH]c23)o1		CHEMBL3717682	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365756	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ccn(C)n4)c3[nH]2)ccc1Cl		CHEMBL3716467	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365757	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc[nH]n5)c4[nH]3)ccc21		CHEMBL3719030	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365758	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncc(C)s4)c3[nH]2)ccc1Cl		CHEMBL3717064	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365759	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3nccs3)cnn12		CHEMBL3714803	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365760	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1csc(-c2cnn3c(=O)cc(-c4ccc(Cl)cc4)[nH]c23)n1		CHEMBL3719129	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365761	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5noc6ccccc56)c4[nH]3)ccc21		CHEMBL3719284	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365762	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5ncc(-c6ccccc6)o5)c4[nH]3)ccc21		CHEMBL3716131	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365763	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(OC)c3)[nH]c12		CHEMBL3719144	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365764	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3716182	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365765	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc4c(cnn4CC)c3)[nH]c12		CHEMBL3715309	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365766	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc(C)n[nH]5)c4[nH]3)ccc21		CHEMBL3716421	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365767	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4cc(C)n[nH]4)c3[nH]2)ccc1Cl		CHEMBL3715831	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365768	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	O=c1cc(-c2ccc(Cl)c(Cl)c2)[nH]c2c(-c3cc[nH]n3)cnn12		CHEMBL3716006	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365769	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cn1ncc2cc(-c3cc(=O)n4ncc(-c5cc[nH]n5)c4[nH]3)ccc21		CHEMBL3718395	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365770	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cn1ncc2cc(-c3cc(=O)n4ncc(-c5ncco5)c4[nH]3)ccc21		CHEMBL3718994	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365771	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1noc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5C)c4)[nH]c23)n1		CHEMBL3718341	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365772	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ccnn4C)c3[nH]2)ccc1F		CHEMBL3719055	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365773	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cn1ccc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5C)c4)[nH]c23)n1		CHEMBL3715182	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365774	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5n[nH]cc5C)c4[nH]3)ccc21		CHEMBL3718079	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365775	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5c(C)cnn5C)c4[nH]3)ccc21		CHEMBL3718799	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365776	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc(C)no5)c4[nH]3)ccc21		CHEMBL3715909	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365777	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5oncc5C)c4[nH]3)ccc21		CHEMBL3716791	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365778	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	COc1cc(-c2cc(=O)n3ncc(CC#N)c3[nH]2)ccc1Cl		CHEMBL3716652	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365779	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5onc(C)c5c4)[nH]c23)o1		CHEMBL3715407	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365780	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c12		CHEMBL3718306	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365781	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(OCC(F)(F)F)c3)[nH]c12		CHEMBL3717971	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365782	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(Cl)c3)[nH]c12		CHEMBL3717911	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365783	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cn1ccc(-c2cnn3c(=O)cc(-c4ccc(Cl)c(OCC(F)(F)F)c4)[nH]c23)n1		CHEMBL3716379	>	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365784	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(Cl)c3)[nH]c12		CHEMBL3718295	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16365785	CHEMBL3721096	Inhibition of GST-tagged full-length purified human CK2a2 using RRRDDDSDDD substrate incubated for 120 mins in presence of [33P]ATP by scintillation counting based biochemical assay	B	Cc1noc(-c2cnn3c(=O)cc(-c4ccc(Cl)c(Cl)c4)[nH]c23)n1		CHEMBL3716495	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16388298	CHEMBL3737355	Inhibition of CK2alpha2 (unknown origin) at 1 uM by selectscreen kinase profiling assay in presence of ATP	B	COc1cc2c(cc1OC)CN(CC(=O)Nc1ccc3c(c1)/C(=C/c1cnc[nH]1)C(=O)N3)CC2		CHEMBL3091673	=	Inhibition	%	11.0	CHEMBL4070	Homo sapiens	INH	%	11.0
	16431787	CHEMBL3748991	Inhibition of human CK2alpha2 using as [RRRDDDSDDD] substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	16463673	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)nc3)s2)cc1		CHEMBL3760043	=	IC50	nM	4.6	CHEMBL4070	Homo sapiens	IC50	uM	0.0046
	16463674	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	IC50	nM	11.0	CHEMBL4070	Homo sapiens	IC50	uM	0.011
	16463675	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	11.0	CHEMBL4070	Homo sapiens	IC50	uM	0.011
	16463694	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cn3)s2)cc1		CHEMBL3759755	=	IC50	nM	10.0	CHEMBL4070	Homo sapiens	IC50	uM	0.01
	16463695	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)nn3)s2)cc1		CHEMBL3758317	=	IC50	nM	9.6	CHEMBL4070	Homo sapiens	IC50	uM	0.0096
	16463696	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)c4ccccc34)s2)cc1		CHEMBL3758475	=	IC50	nM	280.0	CHEMBL4070	Homo sapiens	IC50	uM	0.28
	16463697	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3Oc3ccccc3)s2)cc1		CHEMBL3758519	=	IC50	nM	10.0	CHEMBL4070	Homo sapiens	IC50	uM	0.01
	16463698	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3)s2)cc1		CHEMBL3758270	=	IC50	nM	12.0	CHEMBL4070	Homo sapiens	IC50	uM	0.012
	16463699	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3COc3ccccc3)s2)cc1		CHEMBL3760064	=	IC50	nM	12.0	CHEMBL4070	Homo sapiens	IC50	uM	0.012
	16463700	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCCc3ccccc3)s2)cc1		CHEMBL3760009	=	IC50	nM	11.0	CHEMBL4070	Homo sapiens	IC50	uM	0.011
	16463701	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3Cl)s2)cc1		CHEMBL3759512	=	IC50	nM	9.8	CHEMBL4070	Homo sapiens	IC50	uM	0.0098
	16463702	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3cccc(Cl)c3)s2)cc1		CHEMBL3759388	=	IC50	nM	160.0	CHEMBL4070	Homo sapiens	IC50	uM	0.16
	16463703	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccc(Cl)cc3)s2)cc1		CHEMBL3759193	=	IC50	nM	19.0	CHEMBL4070	Homo sapiens	IC50	uM	0.019
	16463704	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3F)s2)cc1		CHEMBL3759871	=	IC50	nM	8.8	CHEMBL4070	Homo sapiens	IC50	uM	0.0088
	16463705	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3Br)s2)cc1		CHEMBL3758777	=	IC50	nM	14.0	CHEMBL4070	Homo sapiens	IC50	uM	0.014
	16463706	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3OC)s2)cc1		CHEMBL3758895	=	IC50	nM	13.0	CHEMBL4070	Homo sapiens	IC50	uM	0.013
	16463707	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3C#N)s2)cc1		CHEMBL3759349	=	IC50	nM	11.0	CHEMBL4070	Homo sapiens	IC50	uM	0.011
	16463708	CHEMBL3760461	Inhibition of GST-tagged human CK2alpha' (1 to 350 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccn3)s2)cc1		CHEMBL3758606	=	IC50	nM	9.5	CHEMBL4070	Homo sapiens	IC50	uM	0.0095
	16614433	CHEMBL3817299	Inhibition of human CK2alpha2 at 1 uM using as [RRRDDDSDDD] substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-3.0	CHEMBL4070	Homo sapiens	INH	%	-3.0
	16640430	CHEMBL3824970	Inhibition of full-length human wild type CSNK2A2 expressed in mammalian expression system at 1 uM by KINOMEscan assay	B	CN1CCN(c2ccc(-n3cc(-c4ccncc4OCC4CCNCC4)cn3)cc2)CC1		CHEMBL3824068	=	Inhibition	%	66.0	CHEMBL4070	Homo sapiens	INH	%	66.0
	16641947	CHEMBL3826403	Inhibition of GST-tagged full-length human recombinant CSNK2A2 expressed in baculovirus system at 100 nM by Z-lyte assay	B	O=C(CNC(=O)c1cccn(Cc2ccc(F)c(F)c2)c1=O)Nc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL3824119	=	Inhibition	%	3.0	CHEMBL4070	Homo sapiens	INH	%	3.0
	16777162	CHEMBL3864824	Competitive binding affinity to full length wild type human CSNK2A2 expressed in mammalian expression system at 10 uM by kinomescan method relative to control	B	C[C@@H]1C[C@H](N)CN(c2ccncc2Nc2ncc3ccc(-c4c(F)cccc4F)nn23)C1		CHEMBL3942186	=	Activity	%	2.0	CHEMBL4070	Homo sapiens	Activity	%	2.0
	16896859	CHEMBL3882348	Inhibition of human CK2alpha2 assessed as residual activity using RRRDDDSDDD as substrate in presence of [gamma-33P]-ATP	B	Cc1ccc(N/C=C2\C(=O)CCc3c2oc2c(Cl)c(Cl)c(O)cc32)cc1		CHEMBL3920024	=	Activity	%	35.0	CHEMBL4070	Homo sapiens	Activity	%	35.0
Inactive	17894978	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17894979	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	28872.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	28872.0
Inactive	17894980	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894981	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17894982	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	=	Kd	nM	3956.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3956.0
Inactive	17894983	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17894984	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	=	Kd	nM	3017.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3017.0
Inactive	17894985	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17894986	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	394.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	394.0
Inactive	17894987	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894988	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894989	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17894990	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	=	Kd	nM	3229.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3229.0
Active	17894991	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	2635.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2635.0
Active	17894992	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Kd	nM	1.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1.0
Active	17894993	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	103.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	103.0
Inactive	17894994	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894995	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894996	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894997	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894998	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17894999	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895000	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895001	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Kd	nM	5535.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	5535.0
Inactive	17895002	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895003	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895004	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895005	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17895006	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	=	Kd	nM	2807.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2807.0
Inactive	17895007	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895008	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	=	Kd	nM	16348.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	16348.0
Inactive	17895009	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895010	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895011	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895012	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895013	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895014	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895015	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895016	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895017	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	15.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	15.0
Active	17895018	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	10.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	10.0
Inactive	17895019	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895020	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	3201.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3201.0
Inactive	17895021	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895022	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895023	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895024	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	8.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	8.0
Inactive	17895025	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895026	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	=	Kd	nM	584.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	584.0
Inactive	17895027	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895028	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895029	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895030	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895031	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Kd	nM	412.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	412.0
Active	17895032	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	2435.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2435.0
Inactive	17895033	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895034	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895035	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895036	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895037	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895038	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895039	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895040	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895041	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895042	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895043	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895044	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895045	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895046	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	=	Kd	nM	960.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	960.0
Inactive	17895047	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895048	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895049	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Kd	nM	19.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	19.0
Active	17895050	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	=	Kd	nM	7924.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	7924.0
Inactive	17895051	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895052	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895053	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895054	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895055	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895056	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	3153.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3153.0
Inactive	17895057	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895058	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895059	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895060	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895061	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895062	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895063	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	3843.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3843.0
Active	17895064	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	998.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	998.0
Inactive	17895065	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895066	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895067	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895068	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895069	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895070	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895071	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895072	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895073	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	302.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	302.0
Inactive	17895074	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895075	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895076	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	=	Kd	nM	22.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	22.0
Inactive	17895077	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895078	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895079	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895080	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895081	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895082	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	=	Kd	nM	1628.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1628.0
Inactive	17895083	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895084	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895085	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895086	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895087	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895088	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	=	Kd	nM	8487.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	8487.0
Inactive	17895089	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895090	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895091	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895092	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895093	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895094	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895095	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	512.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	512.0
Inactive	17895096	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895097	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895098	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895099	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895100	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895101	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895102	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895103	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895104	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895105	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895106	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895107	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895108	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895109	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895110	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895111	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895112	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895113	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895114	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895115	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	=	Kd	nM	7149.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	7149.0
Inactive	17895116	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895117	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895118	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895119	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895120	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895121	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895122	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895123	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1339.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1339.0
Inactive	17895124	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895125	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895126	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895127	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895128	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895129	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895130	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895131	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895132	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895133	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895134	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895135	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	=	Kd	nM	3422.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3422.0
Inactive	17895136	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895137	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895138	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895139	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895140	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895141	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895142	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	=	Kd	nM	488.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	488.0
Inactive	17895143	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895144	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895145	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	3796.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3796.0
Active	17895146	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	1201.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1201.0
Inactive	17895147	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895148	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895149	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895150	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895151	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895152	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895153	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	=	Kd	nM	1882.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1882.0
Active	17895154	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	10934.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	10934.0
Inactive	17895155	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895156	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895157	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895158	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895159	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895160	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895161	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895162	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	=	Kd	nM	4414.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	4414.0
Inactive	17895163	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895164	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	6582.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	6582.0
Inactive	17895165	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895166	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895167	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	=	Kd	nM	3496.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	3496.0
Inactive	17895168	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895169	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895170	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2619.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2619.0
Inactive	17895171	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895172	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895173	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895174	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895175	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895176	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895177	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895178	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	=	Kd	nM	1604.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1604.0
Inactive	17895179	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895180	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	=	Kd	nM	1543.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1543.0
Inactive	17895181	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895182	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895183	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895184	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895185	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895186	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	=	Kd	nM	2744.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2744.0
Inactive	17895187	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895188	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	65.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	65.0
Inactive	17895189	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895190	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895191	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	=	Kd	nM	2302.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2302.0
Active	17895192	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	=	Kd	nM	17.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	17.0
Inactive	17895193	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895194	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895195	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895196	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895197	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	=	Kd	nM	14757.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	14757.0
Inactive	17895198	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895199	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	=	Kd	nM	279.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	279.0
Inactive	17895200	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895201	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895202	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895203	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895204	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17895205	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	=	Kd	nM	1947.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	1947.0
Inactive	17895206	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895207	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895208	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895209	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	=	Kd	nM	2217.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2217.0
Inactive	17895210	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895211	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895212	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895213	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895214	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895215	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Active	17895216	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	=	Kd	nM	2859.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2859.0
Active	17895217	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Kd	nM	2103.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	2103.0
Inactive	17895218	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17895219	CHEMBL3991681	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL4070	Homo sapiens	Kd apparent	nM	30000.0
	18114412	CHEMBL4025082	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	18203606	CHEMBL4043893	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	18253620	CHEMBL4055094	Inhibition of wild-type human full length CK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	92.0	CHEMBL4070	Homo sapiens	Activity	%	92.0
	18253621	CHEMBL4055094	Inhibition of wild-type human full length CK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	85.0	CHEMBL4070	Homo sapiens	Activity	%	85.0
	18407900	CHEMBL4151456	Inhibition of human CSNK2A2 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(CO)nccc12		CHEMBL4066450	=	Activity	%	37.0	CHEMBL4070	Homo sapiens	Activity	%	37.0
	18407941	CHEMBL4151456	Inhibition of human CSNK2A2 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(C)nc(CO)cc12		CHEMBL4173266	=	Activity	%	2.3	CHEMBL4070	Homo sapiens	Activity	%	2.3
	18407986	CHEMBL4151456	Inhibition of human CSNK2A2 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	23.0	CHEMBL4070	Homo sapiens	Activity	%	23.0
	18440148	CHEMBL4156972	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	18443267	CHEMBL4157902	Displacement of ARC-1504/ARC-1513-5O from CK2alpha' (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)s4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4169451	=	Time	microsec	62.0	CHEMBL4070	Homo sapiens	Time	microsec	62.0
	18443268	CHEMBL4157902	Displacement of ARC-1504/ARC-1513-5O from CK2alpha' (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4172847	=	Time	microsec	39.0	CHEMBL4070	Homo sapiens	Time	microsec	39.0
Not Determined	18443294	CHEMBL4157904	Displacement of ARC-1504/ARC-1513-5O from CK2alpha' (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1		CHEMBL4172847		Time			CHEMBL4070	Homo sapiens	Time		
	18484588	CHEMBL4185751	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	83.0	CHEMBL4070	Homo sapiens	Activity	%	83.0
	18485033	CHEMBL4185751	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	18655584	CHEMBL4230651	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	88.0	CHEMBL4070	Homo sapiens	Activity	%	88.0
	18702499	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4278211	=	Inhibition	%	-1.0	CHEMBL4070	Homo sapiens	INH	%	-1.0
	18702540	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4282644	=	Inhibition	%	0.0	CHEMBL4070	Homo sapiens	INH	%	0.0
	18702584	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1ccc(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4287097	=	Inhibition	%	5.0	CHEMBL4070	Homo sapiens	INH	%	5.0
	18702636	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(N)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4283739	=	Inhibition	%	6.0	CHEMBL4070	Homo sapiens	INH	%	6.0
	18702680	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(C(N)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4294318	=	Inhibition	%	1.0	CHEMBL4070	Homo sapiens	INH	%	1.0
	18702723	CHEMBL4255108	Inhibition of recombinant full length human GST-tagged CSNK2A2 expressed in baculovirus expression system at 1 uM relative to control	B	COc1cc(C)c(S(C)(=O)=O)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1		CHEMBL4289040	=	Inhibition	%	3.0	CHEMBL4070	Homo sapiens	INH	%	3.0
	18751663	CHEMBL4264240	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	99.0	CHEMBL4070	Homo sapiens	Activity	%	99.0
	18761464	CHEMBL4266542	Inhibition of human CK2A2 at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	-3.0	CHEMBL4070	Homo sapiens	INH	%	-3.0
	18761760	CHEMBL4266542	Inhibition of human CK2A2 at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	7.0	CHEMBL4070	Homo sapiens	INH	%	7.0
	18761923	CHEMBL4266542	Inhibition of human CK2A2 at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-6.0	CHEMBL4070	Homo sapiens	INH	%	-6.0
	18857909	CHEMBL4307755	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	78.0	CHEMBL4070	Homo sapiens	Activity	%	78.0
	18937835	CHEMBL4327648	Inhibition of human CK2A2 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	117.0	CHEMBL4070	Homo sapiens	Activity	%	117.0
	18937836	CHEMBL4327648	Inhibition of human CK2A2 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	121.9	CHEMBL4070	Homo sapiens	Activity	%	121.9
	18938488	CHEMBL4328008	Inhibition of human CK2A2 assessed as residual activity at 100 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL4070	Homo sapiens	Activity	%	65.0
	18938864	CHEMBL4328372	Inhibition of human CK2A2 using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	844.0	CHEMBL4070	Homo sapiens	IC50	10'-7M	8.44
	18958826	CHEMBL4333345	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	18989211	CHEMBL4340753	Inhibition of recombinant human full-length N-terminal GST-His6-fused CK2-alpha2 (M1 to R350 residues) expressed in Sf9 insect cells using casein as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	=	IC50	nM	99000.0	CHEMBL4070	Homo sapiens	IC50	uM	99.0
	19009360	CHEMBL4345232	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as enzyme activity at 1 uM by Kinomescan method relative to control	B	Cc1ccc(-n2ccc3c(Nc4cccc(NC(=O)c5ccc(NC(=O)/C=C/CN(C)C)cc5)c4)ncnc32)cc1		CHEMBL4439287	=	Activity	%	90.0	CHEMBL4070	Homo sapiens	Activity	%	90.0
	19009361	CHEMBL4345232	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as enzyme activity at 1 uM by Kinomescan method relative to control	B	CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2cccc(Nc3cc(-c4c[nH]c5ccccc45)ncn3)c2)cc1		CHEMBL4446338	=	Activity	%	1.3	CHEMBL4070	Homo sapiens	Activity	%	1.3
Active	19041066	CHEMBL4352327	Inhibition of human CK2A2 at 10 uM using RRRDDDSDDD as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
	19059528	CHEMBL4357829	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	19090099	CHEMBL4365673	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	32.0	CHEMBL4070	Homo sapiens	Activity	%	32.0
	19091881	CHEMBL4366355	Inhibition of human CK2A2 at 100 nM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	19.82	CHEMBL4070	Homo sapiens	INH	%	19.82
	19159356	CHEMBL4382460	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	19191651	CHEMBL4389179	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	91.0	CHEMBL4070	Homo sapiens	INH	%	91.0
	19191842	CHEMBL4389656	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	81.0	CHEMBL4070	Homo sapiens	INH	%	81.0
	19199940	CHEMBL4391282	Binding affinity to wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	5.0	CHEMBL4070	Homo sapiens	Activity	%	5.0
	19242715	CHEMBL4400050	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate incubated for 40 mins in presence of [gamma-33P]ATP at Km concentration by radiometric assay relative to control	B	COc1ccc2c(CCNc3nc(NCc4ccc(=O)[nH]c4)c4nc[nH]c4n3)c[nH]c2c1		CHEMBL4555782	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	19266377	CHEMBL4405327	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	19276004	CHEMBL4408007	Inhibition of recombinant human full length CK2alpha2 at 1 uM using RRRDDDSDDD as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	72.0	CHEMBL4070	Homo sapiens	INH	%	72.0
	19330199	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ncco1		CHEMBL3715226	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330200	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)o1		CHEMBL3718846	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330201	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1coc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)n1		CHEMBL3717312	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330202	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5[nH]nnc5c4)[nH]c23)o1		CHEMBL3715057	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330203	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5nc(C)co5)c4[nH]3)ccc21		CHEMBL3718043	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330204	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCc1coc(-c2cnn3c(=O)cc(-c4ccc5[nH]nnc5c4)[nH]c23)n1		CHEMBL3715959	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330205	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCc1coc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCO5)[nH]c23)n1		CHEMBL3717585	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330206	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncc(C)o4)c3[nH]2)ccc1Cl		CHEMBL3714819	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330207	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4nc(C)co4)c3[nH]2)ccc1Cl		CHEMBL3717056	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330208	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncco4)c3[nH]2)ccc1Cl		CHEMBL3716116	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330209	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5ncco5)c4[nH]3)ccc21		CHEMBL3717677	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330210	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCOc1cc(-c2cc(=O)n3ncc(-c4nc(C)co4)c3[nH]2)ccc1Cl		CHEMBL3716329	>	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330211	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3[nH]ncc3c2)[nH]c2c(-c3ncco3)cnn12		CHEMBL3717303	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330212	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	C#CCNC(=O)c1cnn2c(=O)cc(-c3ccc4[nH]ncc4c3)[nH]c12		CHEMBL4463863	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330213	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCc1cnc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5CC)c4)[nH]c23)o1		CHEMBL3717682	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330214	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ccn(C)n4)c3[nH]2)ccc1Cl		CHEMBL3716467	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330215	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc[nH]n5)c4[nH]3)ccc21		CHEMBL3719030	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330216	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ncc(C)s4)c3[nH]2)ccc1Cl		CHEMBL3717064	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330217	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3nccs3)cnn12		CHEMBL3714803	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330218	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1csc(-c2cnn3c(=O)cc(-c4ccc(Cl)cc4)[nH]c23)n1		CHEMBL3719129	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330219	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5noc6ccccc56)c4[nH]3)ccc21		CHEMBL3719284	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330220	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5ncc(-c6ccccc6)o5)c4[nH]3)ccc21		CHEMBL3716131	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330221	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(OC)c3)[nH]c12		CHEMBL3719144	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330222	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3716182	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330223	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc4c(cnn4CC)c3)[nH]c12		CHEMBL3715309	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330224	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc(C)n[nH]5)c4[nH]3)ccc21		CHEMBL3716421	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330225	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4cc(C)n[nH]4)c3[nH]2)ccc1Cl		CHEMBL3715831	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330226	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)c(Cl)c2)[nH]c2c(-c3cc[nH]n3)cnn12		CHEMBL3716006	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330227	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cn1ncc2cc(-c3cc(=O)n4ncc(-c5cc[nH]n5)c4[nH]3)ccc21		CHEMBL3718395	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330228	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cn1ncc2cc(-c3cc(=O)n4ncc(-c5ncco5)c4[nH]3)ccc21		CHEMBL3718994	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330229	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1noc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5C)c4)[nH]c23)n1		CHEMBL3718341	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330230	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(-c4ccnn4C)c3[nH]2)ccc1F		CHEMBL3719055	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330231	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cn1ccc(-c2cnn3c(=O)cc(-c4ccc5c(cnn5C)c4)[nH]c23)n1		CHEMBL3715182	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330232	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5n[nH]cc5C)c4[nH]3)ccc21		CHEMBL3718079	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330233	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5c(C)cnn5C)c4[nH]3)ccc21		CHEMBL3718799	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330234	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5cc(C)no5)c4[nH]3)ccc21		CHEMBL3715909	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330235	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1ncc2cc(-c3cc(=O)n4ncc(-c5oncc5C)c4[nH]3)ccc21		CHEMBL3716791	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330236	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc(-c2cc(=O)n3ncc(CC#N)c3[nH]2)ccc1Cl		CHEMBL3716652	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330237	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1cnc(-c2cnn3c(=O)cc(-c4ccc5onc(C)c5c4)[nH]c23)o1		CHEMBL3715407	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330238	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c12		CHEMBL3718306	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330239	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(OCC(F)(F)F)c3)[nH]c12		CHEMBL3717971	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330240	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(Cl)c3)[nH]c12		CHEMBL3717911	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330241	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cn1ccc(-c2cnn3c(=O)cc(-c4ccc(Cl)c(OCC(F)(F)F)c4)[nH]c23)n1		CHEMBL3716379	>	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330242	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cn1nccc1-c1cnn2c(=O)cc(-c3ccc(Cl)c(Cl)c3)[nH]c12		CHEMBL3718295	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19330243	CHEMBL4418658	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1noc(-c2cnn3c(=O)cc(-c4ccc(Cl)c(Cl)c4)[nH]c23)n1		CHEMBL3716495	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454871	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3717062	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454872	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccc1		CHEMBL4561156	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454873	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccc1		CHEMBL3717800	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454874	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3717873	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454875	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3715111	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454876	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3717141	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454877	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3718833	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454878	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccn1		CHEMBL3714956	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454879	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1cccnc1		CHEMBL3717739	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454880	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccc(F)cc4)c3[nH]2)cc1		CHEMBL3717491	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454881	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)CCO4)[nH]c2c1-c1ccccc1		CHEMBL3717687	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454882	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1		CHEMBL3716647	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454883	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717429	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454884	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1Cc1ccccc1		CHEMBL3719324	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454885	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc(OC(C)C)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717587	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454886	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)cc1		CHEMBL4564110	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454887	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COC(=O)c1ccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)cc1		CHEMBL3718477	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454888	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc(C(N)=O)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3718878	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454889	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc(C(F)(F)F)cc3)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3717637	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454890	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccccc4)c3[nH]2)cc1OC		CHEMBL3715144	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454891	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccc(Cl)cc4)c3[nH]2)cc1OC		CHEMBL3718262	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454892	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3nc(C)c(Cc4ccccc4Cl)c3[nH]2)cc1		CHEMBL3718613	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454893	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCc1c(C)nn2c(=O)cc(-c3ccc(OC)cc3)[nH]c12		CHEMBL3716589	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454894	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4cccnc4)c3[nH]2)cc1		CHEMBL3718928	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454895	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4ncccc4c3)[nH]c2c1Cc1ccccc1		CHEMBL3715308	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454896	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4cc[nH]c4c3)[nH]c2c1Cc1ccccc1		CHEMBL3717516	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454897	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1cccc(Cl)c1		CHEMBL3718072	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454898	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1ccc(Cl)cc1		CHEMBL3718717	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454899	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3cccnc3)[nH]c2c1-c1ccc(F)cc1		CHEMBL3716356	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454900	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccccn2)[nH]c2c(-c3ccc(F)cc3)cnn12		CHEMBL3715012	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454901	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccc(F)cc1		CHEMBL3716034	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454902	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccc(N4CCCCC4)nc3)cnn12		CHEMBL3716458	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454903	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3cccc(F)c3)cnn12		CHEMBL3716381	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454904	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cccc(-c2cnn3c(=O)cc(-c4ccc5c(c4)OCCO5)[nH]c23)c1		CHEMBL3715752	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454905	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2cc3ccccc3o2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715315	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454906	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3cc[nH]c3c2)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3715239	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454907	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3716831	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454908	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3718504	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454909	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccc3)cnn12		CHEMBL3715727	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454910	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3715734	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454911	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3716856	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454912	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3714800	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454913	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3717465	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454914	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccc3)c(O)nn12		CHEMBL3714834	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454915	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=C(c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12)N1CCOCC1		CHEMBL3718364	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454916	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CN1CCN(C(=O)c2cnn3c(=O)cc(-c4ccc5c(c4)OCCO5)[nH]c23)CC1		CHEMBL3716985	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454917	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=C(NCc1ccccc1)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3716799	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454918	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3718186	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454919	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)c(OC)c1		CHEMBL3717548	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454920	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1OC		CHEMBL3716419	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454921	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	N#Cc1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3719132	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454922	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	NC(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3715534	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454923	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1c2c([nH]c3c(-c4ccccn4)cnn13)-c1ccccc1CC2		CHEMBL3715277	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454924	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn12		CHEMBL3718125	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454925	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCCO3)[nH]c2c(-c3ccc(N4CCCC4)nc3)cnn12		CHEMBL3714936	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454926	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc2c(c1)CCc1c-2[nH]c2c(-c3ccccn3)cnn2c1=O		CHEMBL3719187	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454927	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccc(-c2cc(=O)n3nc(O)c(-c4ccccn4)c3[nH]2)c(OC)c1		CHEMBL3718915	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454928	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3719218	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454929	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715245	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454930	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)c(Cl)c2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3714937	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454931	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccc3)c(O)nn12		CHEMBL3715280	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454932	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(Cl)cc2)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3714911	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454933	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3718933	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454934	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)CCO3)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3717372	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454935	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3719099	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454936	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(Cc3ccccc3)cnn12		CHEMBL3718461	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454937	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1ccccc1-c1cc(=O)n2ncc(-c3ccccn3)c2[nH]1		CHEMBL3716796	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454938	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(F)cc2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3716797	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454939	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c2c1-c1ccccc1		CHEMBL3719372	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454940	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccc1		CHEMBL3717434	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454941	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CN(Cc1ccccc1)C(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3719350	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454942	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=C(NCc1ccccc1)c1cnn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3716028	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454943	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1cnn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c12		CHEMBL3716004	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454944	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3occc3c2)[nH]c2c(-c3cccnc3)c(O)nn12		CHEMBL3718311	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454945	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCCO4)[nH]c2c1-c1ccccn1		CHEMBL3716003	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454946	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3717173	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454947	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c2c1-c1ccccn1		CHEMBL3715729	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454948	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CC(=O)Nc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3716838	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454949	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCNc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3717072	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454950	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OC(F)(F)O3)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715197	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454951	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]ncc4c3)[nH]c2c1-c1ccccn1		CHEMBL3717400	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454952	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3[nH]ncc3c2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3718475	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454953	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1-c1ccccn1		CHEMBL3715306	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454954	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc(Cl)cc3F)[nH]c2c1-c1ccccn1		CHEMBL3715384	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454955	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3c(c2)OCO3)[nH]c2c(-c3ncccc3F)cnn12		CHEMBL3719038	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454956	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc(F)cc3)[nH]c2c1-c1ccccn1		CHEMBL3716009	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454957	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccn1		CHEMBL3719303	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454958	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3ccccn3)c(O)nn12		CHEMBL3717777	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454959	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c12		CHEMBL3716353	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454960	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]ncc4c3)[nH]c12		CHEMBL3717256	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454961	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccc1		CHEMBL3716608	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454962	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccccn1		CHEMBL3718202	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454963	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CC(=O)Nc1nn2c(=O)cc(-c3ccc4c(cnn4C)c3)[nH]c2c1-c1ccccn1		CHEMBL3718184	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454964	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Cc1nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c2c1Cc1ccccn1		CHEMBL3715232	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454965	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3cccnc3)cnn12		CHEMBL3714786	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454966	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1cnn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c12		CHEMBL3715094	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454967	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	Nc1nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c2c1-c1ccc(Cl)cc1		CHEMBL3716007	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454968	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc3[nH]nnc3c2)[nH]c2c(-c3ccc(Cl)cc3)cnn12		CHEMBL3715305	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454969	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]nnc4c3)[nH]c12		CHEMBL3718786	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454970	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc4[nH]nc(C)c4c3)[nH]c12		CHEMBL3715395	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454971	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(N)nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c12		CHEMBL3717588	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454972	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	CCCNC(=O)c1c(O)nn2c(=O)cc(-c3ccc4c(c3)OCO4)[nH]c12		CHEMBL3715749	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454973	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1c(-c2cc(=O)n3nc(N)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3718154	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454974	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1c(-c2cc(=O)n3nc(O)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3718721	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454975	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1c(-c2cc(=O)n3nc(C)c(-c4ccccn4)c3[nH]2)ccc2c1OCO2		CHEMBL3716739	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454976	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1cc2[nH]nnc2cc1-c1cc(=O)n2nc(N)c(-c3ccccn3)c2[nH]1		CHEMBL3717392	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454977	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	COc1c(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)ccc2[nH]nnc12		CHEMBL3715940	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454978	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2cc3nn[nH]c3cc2F)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715630	<=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454979	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	O=c1cc(-c2ccc(-c3ncco3)cc2)[nH]c2c(-c3ccccn3)cnn12		CHEMBL3715461	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	19454980	CHEMBL4476895	Inhibition of GST-tagged full length human CK2a2 expressed in insect cells incubated for 120 mins using RRRDDDSDDD substrate and [33P]-ATP by scintillation counting assay	B	N#Cc1ccc(-c2cc(=O)n3ncc(-c4ccccn4)c3[nH]2)cc1		CHEMBL3716508	>=	IC50	nM	10000.0	CHEMBL4070	Homo sapiens	IC50	uM	10.0
	20600501	CHEMBL4603453	Inhibition of recombinant human full-length GST-tagged CSNK2A2 expressed in baculovirus expression system using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr in presence of ATP by Z'-lyte assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL4070	Homo sapiens	IC50	uM	100.0
	22423707	CHEMBL4674429	Inhibition of human CK2A2 using RRRDDDSDDD as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	100.69	CHEMBL4070	Homo sapiens	Activity	%	100.69
	22423708	CHEMBL4674429	Inhibition of human CK2A2 using RRRDDDSDDD as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	82.72	CHEMBL4070	Homo sapiens	Activity	%	82.72
Active	22793106	CHEMBL4710104	Inhibition of N-terminal His6-tagged CK2alpha' (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells assessed as change in melting temperature at 10 uM by SYPRO Orange dye based DSF assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Active	22793107	CHEMBL4710104	Inhibition of N-terminal His6-tagged CK2alpha' (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells assessed as change in melting temperature at 10 uM by SYPRO Orange dye based DSF assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
Active	22793111	CHEMBL4710107	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819		Inhibition	%		CHEMBL4070	Homo sapiens	INH		
	22793121	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc(-c2cnn3ccc(N(CCOCCO)C(=O)OC(C)(C)C)nc23)cc1O		CHEMBL4744728	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793122	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819	=	IC50	nM	7640.0	CHEMBL4070	Homo sapiens	IC50	uM	7.64
	22793123	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCN(C(=O)OC(C)(C)C)c1ccn3ncc-2c3n1		CHEMBL4779625	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793124	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618	=	IC50	nM	7390.0	CHEMBL4070	Homo sapiens	IC50	uM	7.39
	22793125	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4778998	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793126	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4795226	=	IC50	nM	16200.0	CHEMBL4070	Homo sapiens	IC50	uM	16.2
	22793127	CHEMBL4710111	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	552.0	CHEMBL4070	Homo sapiens	IC50	uM	0.552
	22793135	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc(-c2cnn3ccc(N(CCOCCO)C(=O)OC(C)(C)C)nc23)cc1O		CHEMBL4744728	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793136	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819	=	IC50	nM	38.0	CHEMBL4070	Homo sapiens	IC50	uM	0.038
	22793137	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCN(C(=O)OC(C)(C)C)c1ccn3ncc-2c3n1		CHEMBL4779625	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793138	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618	=	IC50	nM	771.0	CHEMBL4070	Homo sapiens	IC50	uM	0.7709999999999999
	22793139	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4778998	>	IC50	nM	50000.0	CHEMBL4070	Homo sapiens	IC50	uM	50.0
	22793140	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4795226	=	IC50	nM	303.0	CHEMBL4070	Homo sapiens	IC50	uM	0.303
	22793141	CHEMBL4710113	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha' expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	163.0	CHEMBL4070	Homo sapiens	IC50	uM	0.163
	22793203	CHEMBL4710175	Inhibition of recombinant human CK2alpha' in presence of ATP at Km concentration by radiometric filter-binding assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	1.0	CHEMBL4070	Homo sapiens	IC50	nM	1.0
	22815900	CHEMBL4714746	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	CNC(=O)CN(Cc1ccccc1OC(F)F)C(=O)c1c[nH]c(C(=O)N2Cc3ccc(C(N)=O)cc3C2)n1		CHEMBL4752978	>	Inhibition	%	65.0	CHEMBL4070	Homo sapiens	INH	%	65.0
	22843438	CHEMBL4720435	Inhibition of human CK2A2 assessed as residual activity using RRRDDDSDDD as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	96.51	CHEMBL4070	Homo sapiens	Activity	%	96.51
	22843790	CHEMBL4720776	Inhibition of human CK2A2 using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	442.0	CHEMBL4070	Homo sapiens	IC50	10^-7M	4.42
	22844671	CHEMBL4721346	Inhibition of CK2a2 (unknown origin) assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	86.07	CHEMBL4070	Homo sapiens	Activity	%	86.07
	22886567	CHEMBL4728270	Binding affinity to CK2A2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay	B	Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O		CHEMBL1945559	>	Delta Tm	degrees C	4.0	CHEMBL4070	Homo sapiens	deltaTm	degrees C	4.0
	22961287	CHEMBL4768886	Inhibition of CK2alpha' (unknown origin) at 1 uM by PanQuinase assay relative to control	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(Br)s2)ccc1O		CHEMBL4795023	>	Inhibition	%	50.0	CHEMBL4070	Homo sapiens	INH	%	50.0
	23122514	CHEMBL4804865	Inhibition of human CSNK2A2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	64.0	CHEMBL4070	Homo sapiens	Activity	%	64.0
	23123209	CHEMBL4805453	Inhibition of human CSNK2A2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	63.0	CHEMBL4070	Homo sapiens	Activity	%	63.0
	23123682	CHEMBL4805926	Inhibition of DNA-tagged human CSNK2A2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	82.0	CHEMBL4070	Homo sapiens	Activity	%	82.0
	23124508	CHEMBL4806470	Inhibition of human CSNK2A2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	92.0	CHEMBL4070	Homo sapiens	Activity	%	92.0
	23124509	CHEMBL4806470	Inhibition of human CSNK2A2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL4070	Homo sapiens	Activity	%	100.0
	23234004	CHEMBL4827584	Inhibition of wild-type human full length CSNK2A2 (M1 to R350 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	O=C(O)c1ccc(-c2cnn3ccc(-c4ccccc4)nc23)cc1C1CCCC1		CHEMBL4877552	<	Activity	%	10.0	CHEMBL4070	Homo sapiens	Activity	%	10.0
Not Active	23317349	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23317817	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	73.0	CHEMBL4070	Homo sapiens	% Control	%	73.0
Not Active	23318487	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23318967	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23319606	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	98.4	CHEMBL4070	Homo sapiens	% Control	%	98.4
Not Active	23320079	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	77.1	CHEMBL4070	Homo sapiens	% Control	%	77.1
Not Active	23320757	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23321225	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23321855	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	87.0	CHEMBL4070	Homo sapiens	% Control	%	87.0
Not Active	23322323	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	83.0	CHEMBL4070	Homo sapiens	% Control	%	83.0
Not Active	23323012	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	87.0	CHEMBL4070	Homo sapiens	% Control	%	87.0
Not Active	23323480	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23323979	CHEMBL4880598	CK2alpha2 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-2.0	CHEMBL4070	Homo sapiens	% inhibition	%	-2.0
Not Active	23324334	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23324969	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	79.0	CHEMBL4070	Homo sapiens	% Control	%	79.0
Not Active	23325437	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	88.0	CHEMBL4070	Homo sapiens	% Control	%	88.0
Not Active	23326084	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23326552	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23327252	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23327720	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	72.0	CHEMBL4070	Homo sapiens	% Control	%	72.0
Not Active	23328307	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23328775	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23329302	CHEMBL4881009	CK2alpha2 (h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	94.0	CHEMBL4070	Homo sapiens	% residual kinase activity	%	94.0
Not Active	23329721	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	93.0	CHEMBL4070	Homo sapiens	% Control	%	93.0
Not Active	23330189	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	85.0	CHEMBL4070	Homo sapiens	% Control	%	85.0
Not Active	23330945	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23331413	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	90.0	CHEMBL4070	Homo sapiens	% Control	%	90.0
Not Active	23332000	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	82.4	CHEMBL4070	Homo sapiens	% Control	%	82.4
Not Active	23332468	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23333184	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	75.7	CHEMBL4070	Homo sapiens	% Control	%	75.7
Not Active	23333648	CHEMBL4881451	CK2alpha2(h) Eurofins Kinase panel	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% residual kinase activity	%	67.0	CHEMBL4070	Homo sapiens	% residual kinase activity	%	67.0
Not Active	23333823	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23334291	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23335270	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	86.0	CHEMBL4070	Homo sapiens	% Control	%	86.0
Not Active	23335738	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	89.0	CHEMBL4070	Homo sapiens	% Control	%	89.0
Not Active	23336365	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	92.0	CHEMBL4070	Homo sapiens	% Control	%	92.0
Not Active	23336833	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	85.0	CHEMBL4070	Homo sapiens	% Control	%	85.0
Not Active	23337561	CHEMBL4881932	CSNK2A2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	94.5	CHEMBL4070	Homo sapiens	% Ctrl	%	94.5
Not Active	23337914	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	90.0	CHEMBL4070	Homo sapiens	% Control	%	90.0
Not Active	23338382	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23338994	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	92.0	CHEMBL4070	Homo sapiens	% Control	%	92.0
Not Active	23339462	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	83.0	CHEMBL4070	Homo sapiens	% Control	%	83.0
Not Active	23340099	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	80.0	CHEMBL4070	Homo sapiens	% Control	%	80.0
Not Active	23340567	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23341224	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23341692	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23342308	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23342776	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23343406	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	87.0	CHEMBL4070	Homo sapiens	% Control	%	87.0
Not Active	23343874	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23344512	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23345085	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23345553	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23346130	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23346599	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	59.8	CHEMBL4070	Homo sapiens	% Control	%	59.8
Not Active	23347207	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	76.0	CHEMBL4070	Homo sapiens	% Control	%	76.0
Not Active	23347690	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23348269	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23348737	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23349324	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	99.0	CHEMBL4070	Homo sapiens	% Control	%	99.0
Not Active	23349942	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23350410	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	84.0	CHEMBL4070	Homo sapiens	% Control	%	84.0
Not Active	23351015	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23351483	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23352012	CHEMBL4882703	CSNK2A2 (CK2 alpha 2) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	10.45	CHEMBL4070	Homo sapiens	% Inhibition	%	10.4508
Not Active	23352507	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23352975	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	86.0	CHEMBL4070	Homo sapiens	% Control	%	86.0
Not Active	23353857	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23354325	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23355057	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23355525	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	88.0	CHEMBL4070	Homo sapiens	% Control	%	88.0
Not Active	23356161	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23356629	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23357238	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	86.0	CHEMBL4070	Homo sapiens	% Control	%	86.0
Not Active	23357885	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23358353	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23358939	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	79.4	CHEMBL4070	Homo sapiens	% Control	%	79.4
Not Active	23359537	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23360005	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23360590	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	84.0	CHEMBL4070	Homo sapiens	% Control	%	84.0
Not Active	23361058	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	98.0	CHEMBL4070	Homo sapiens	% Control	%	98.0
Not Active	23361631	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	91.0	CHEMBL4070	Homo sapiens	% Control	%	91.0
Not Active	23362167	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	91.0	CHEMBL4070	Homo sapiens	% Control	%	91.0
Not Active	23362635	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	96.0	CHEMBL4070	Homo sapiens	% Control	%	96.0
Not Active	23364277	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23364745	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23365484	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23366027	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23366617	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23367085	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	88.0	CHEMBL4070	Homo sapiens	% Control	%	88.0
Not Active	23367519	CHEMBL4883872	CK2-alpha2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	87.0	CHEMBL4070	Homo sapiens	% Residual activity with Skepinone-L	%	87.0
Not Active	23367963	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23368431	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23369030	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23369498	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	78.0	CHEMBL4070	Homo sapiens	% Control	%	78.0
Not Active	23370024	CHEMBL4884268	CK2alpha2(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	109.0	CHEMBL4070	Homo sapiens	% residual kinase activity	%	109.0
Not Active	23370466	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23370934	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23371743	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23372211	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	85.0	CHEMBL4070	Homo sapiens	% Control	%	85.0
	23372715	CHEMBL4884680	CK2alpha2(C2A2LGK1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL4070	Homo sapiens	pIC50		6.0
	23373124	CHEMBL4884971	CK2alpha2(C2A2LGK1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL4070	Homo sapiens	pIC50		6.0
	23373485	CHEMBL4885262	CK2alpha2(C2A2LGK1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL4070	Homo sapiens	pIC50		6.0
Not Active	23375638	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	76.0	CHEMBL4070	Homo sapiens	% Control	%	76.0
Not Active	23376106	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	83.0	CHEMBL4070	Homo sapiens	% Control	%	83.0
Not Active	23376683	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	92.0	CHEMBL4070	Homo sapiens	% Control	%	92.0
Not Active	23377153	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23378011	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23378479	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	90.0	CHEMBL4070	Homo sapiens	% Control	%	90.0
Not Active	23379646	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	86.0	CHEMBL4070	Homo sapiens	% Control	%	86.0
Not Active	23380114	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	98.0	CHEMBL4070	Homo sapiens	% Control	%	98.0
Not Active	23380808	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23381456	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	99.0	CHEMBL4070	Homo sapiens	% Control	%	99.0
Not Active	23381924	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Slightly Active	23382548	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	28.0	CHEMBL4070	Homo sapiens	% Control	%	28.0
Active	23383016	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	6.7	CHEMBL4070	Homo sapiens	% Control	%	6.7
Not Active	23383756	CHEMBL4887398	CSNK2A2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	87.0	CHEMBL4070	Homo sapiens	% Ctrl	%	87.0
Not Active	23384230	CHEMBL4887825	CK2alpha2(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-4.36	CHEMBL4070	Homo sapiens	% inhibition	%	-4.36
Not Active	23384931	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23385398	CHEMBL4879655	KinomeScan assay: inhibition of CSNK2A2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL4070	Homo sapiens	% Control	%	100.0
Not Active	23385875	CHEMBL4888348	CK2alpha2 Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	4.0	CHEMBL4070	Homo sapiens	% inhibition	%	4.0
